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Abstract 
In spite of promising preclinical results there is a decreasing number of new registered 
medications in major depression. The main reason behind this fact is the lack of confirmation 
in clinical studies for the assumed, and in animals confirmed, therapeutic results. This 
suggests low predictive value of animal studies for central nervous system disorders. One 
solution for identifying new possible targets is the application of genetics and genomics, 
which may pinpoint new targets based on the effect of genetic variants in humans. The 
present review summarizes such research focusing on depression and its therapy. The 
inconsistency between most genetic studies in depression suggests, first of all, a significant 
role of environmental stress. Furthermore, effect of individual genes and polymorphisms is 
weak, therefore gene x gene interactions or complete biochemical pathways should be 
analyzed. Even genes encoding target proteins of currently used antidepressants remain non-
significant in genome-wide case control investigations suggesting no main effect in 
depression, but rather an interaction with stress. The few significant genes in GWASs are 
related to neurogenesis, neuronal synapse, cell contact and DNA transcription and as being 
nonspecific for depression are difficult to harvest pharmacologically. Most candidate genes in 
replicable GxE interactions, on the other hand, are connected to the regulation of stress and 
the HPA axis and thus could serve as drug targets for a depression subgroups characterized by 
stress-sensitivity and anxiety while other risk polymorphisms such as those related to 
prominent cognitive symptoms in depression may help to identify additional subgroups and 
their distinct treatment. Until these new targets find their way in the therapy, the optimization 
of current medications can be approached by pharmacogenomics, where metabolizing enzyme 
polymorphisms remain prominent determinants of therapeutic success.  
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Abbreviations 
5HTTLPR Repeat length polymorphism in promoter region of serotonin transporter gene 
ABCB1 ATP Binding Cassette Subfamily B Member 1 
CACNA1E Calcium voltage-gated channel subunit alpha1 E 
CACNA2D1 Calcium voltage-gated channel auxiliary subunit alpha2delta 1 
CEP350 Centrosomal protein 350 
CNR1  Cannabinoid receptor 1  
CNV Copy number variation 
COMT Cathecol-o-methyltransferase  
CREB cAMP responsive element binding protein 
CRHR1 Corticotropin releasing hormone receptor 1 
CYP Cytochrome P450 
DCC Dcc netrin 1 receptor 
DRD2 Dopamine receptor D2 
DSM-5 Diagnostic and Statistical Manual of Mental Disorders, 5
th
 Edition 
ExE Environment-environment interaction 
FAAH   Fatty acid amide hydrolase  
FKBP5 FK506 binding protein 5 
GABRA6 Gamma-aminobutyric acid type A receptor alpha6 subunit  
GAL Galanin 
GALR1 Galanin receptor 1 
GALR2 Galanin receptor 2 
GALR3 Galanin receptor 3 
GC Glucocorticoid receptor 
GENDEP Genome-wide Pharmacogenetics of Antidepressant Response 
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GenRED Genetics of Recurrent Early-Onset Depression 
GERA Genetic Epidemiology Research on Adult Health and Aging 
GRIK4 Ionotropic glutamate kainate 4 receptor 
GRIK5 Glutamate ionotropic receptor kainate type subunit 5 
GRM5  Glutamate metabotropic receptor 5 
GWAS Genome-wide association study 
GWS Genome-wide significant 
GxE Gene-environment interaction 
GxG Gene-gene interaction 
HPA Hypothalamus-pituitary-adrenal cortex 
HTR1A Serotonin transporter 1A receptor 
HTR1B Serotonin transporter 1B receptor  
IL1B Interleukine 1 beta 
IL-6 Interleukine 6 
KSR2 Kinase suppressor of ras 2 
LHPP Phospholysine phosphohistidine inorganic pyrophosphate phosphatase 
LRFN5 Leucine rich repeat and fibronectin type III domain containing 5 
MAF Minimal allele frequency 
MAOI Monoaminoxidase inhibitor 
MAOA Monoaminoxidase A  
MDD Major depressive disorder  
MEF2C Myocyte enhancer factor 2C 
MEIS2 Meis homeobox 2 
MESA Multi-Ethnic Study of Atherosclerosis 
MTHFR Methyl-tetrahydrofolate reductase 
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MUC13 Mucin 13, cell surface associated  
NaSSA Noradrenergic and selective serotonergic antidepressant 
NDRI Noradrenaline dopamine reuptake inhibitor 
NEGR1 Neuronal growth regulator 1 
NOS1 Nitric oxide synthase 1 
NRI Noradrenaline reuptake inhibitor 
OLFM4 Olfactomedin 4 
PCDH9 Protocadherin 9 
PCLO Piccolo presynaptic cytomatrix protein  
PGC Psychiatric Genomics Consortium  
PHF21B PHD finger protein 21B 
RBFOX1 RNA binding protein fox-1 homolog 1 
rG Genetic correlation 
RGS10 Regulators of G-protein signaling 10 
SARI Serotonin antagonist and reuptake inhibitor 
SIRT1 Sirtuin 1 
SLC6A2 Solute carrier family 6 member 2 
SLE Stressful life events 
SNP Single nucleotide polymorphism 
SNRI Serotonin noradrenaline reuptake inhibitor 
SSRI Selective serotonin reuptake inhibitor 
STAR*D Sequenced Treatment Alternatives to Relieve Depression 
TCA Tricyclic antidepressant 
TMCO5A Transmembrane and coiled-coil domains 5A 
TMEM161B Transmembrane protein 161B  
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TPH Tryptophan hydroxylase 
VNTR Variable number tandem repeats 
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1. Introduction  
Depression is a widely known diagnosis both for the general public and in the medical 
community, yet its severity and complexity is not sufficiently understood and acknowledged. 
Many equate depression simply with bad mood. Depression, however, is a severe and 
debilitating disease characterized by a wide variety of symptoms, including at least one of the 
2 core criteria referring to depressed mood and loss of interest, motivation or pleasure 
accompanied by at least four of several additional symptoms related to the physical axis 
(appetite, sleep, pain, lack of energy), psychomotor symptoms, and symptoms related to 
cognitive functions (inability to plan or decide, slowed thinking, memory problems, attention 
problems) or the content of cognitions (thoughts of death or dying, suicide, guilt) (Figure 1). 
These symptoms affect patients and society alike through significantly reduced functioning, 
interference with normal activity in the academic/work sphere, social and family domains and 
cause significant suffering and distress. Depression affects more than 300 million people 
worldwide with one in 20 people reporting a depressive episode within one year and the 
disease is currently the leading cause of disability worldwide (WHO, 2017).  
 
In spite of the high prevalence, the huge burden, the extensive research dating back 
nearly half a century and the increasing number of antidepressant medications available, we 
are still far away from being able to treat depression sufficiently. There are severe unmet 
needs concerning the efficacy of antidepressant medications, including 1) the low response 
and remission rates to the first chosen antidepressant, 2) the failure to treat the full spectrum 
of symptoms, 3) the lack of efficacy for a given antidepressant for all subtypes and symptoms, 
4) the significant residual symptoms, 5) the lack of effective long-term relapse prevention, 
and 6) the relatively high prevalence of resistance to antidepressant treatment (Crisafulli et al., 
2011; Rush et al., 2006; Trivedi et al., 2006). These concerns indicate that currently available 
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antidepressive medications targeting the monoaminergic system are far from adequate in 
therapeutic settings. Whether the lack of efficacy results from our neurochemical 
shortcomings in focusing on monoamines or the heterogeneity of depression is yet to be 
understood.  
 
1.1 Endogenous or reactive? Etiopathological factors in the background of depression 
In previous decades depression was alternatingly attributed to internal biological/genetic and 
external environmental factors best reflected by the concepts of endogenous depression and 
reactive depression proposed by Gillespie in 1929 (Gillespie, 1929). The advent of high 
throughput genetic methods reformed the field of mental disorders and the search for genetic 
variants responsible for the disease truly resulted in the identification of causal variants in 
many disorders. This suggested that there are underlying biological/genetic determinants of 
all mental disorders, among them depression, and this idea of endogenous depression at least 
partially can be tracked in the ever-larger genetic and genomic investigations. However, these 
studies including both candidate gene approaches and genome-wide association studies 
(GWASs), although confirmed the overall role of genetic factors in depression e.g. through 
sharpening/refined SNP-heritability estimates, could yield only few replicable, directly 
associated genetic hits refuting the existence of a common, comprehensive genetic 
architecture with few independent factors and, thus, pure endogenous depression.  
 
One obvious explanation is reflected in the current mainstream conceptualization of 
depression as a stress-related disorder with the etiological role of environmental influences in 
its development and manifestation. While numerous environmental stressors are consistently 
proven to be directly involved in the etiology of depression, it is unlikely that these alone 
could be responsible for the development of the disease given the relatively high heritability 
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of this disorder, which leads to the rejection of the idea of a common, pure reactive depression 
too. Rather, effects of both genes and environment are important and they interact, with 
different relative weights in different manifestations and even in different depression cases. In 
support of this, patients with contributing stressors in their anamnesis also show a family 
history for the disease, implicating that investigation of gene-environment interactions (GxE) 
seems more feasible to find etiopathological variants. While GxE interaction effects presented 
additional novel candidates in depression pathophysiology, most of these studies also 
remained heterogeneous. Less well-explored factors, such as gene-gene interactions (GxG), 
environment x environment (ExE) interactions, rare variants, copy number variations (CNVs) 
and epigenetic changes may mask effects. However, a prime candidate for these 
inconsistencies remains the heterogeneity of depression itself.  
 
1.2 One disease with a thousand faces: symptoms and subtypes of depression 
Depression may manifest with a wide spectrum of symptoms, with differing severity and also 
temporal characteristics and most clinicians and researchers agree that major depressive 
disorder is an umbrella term. This heterogeneity can be grasped from multiple angles and at 
least two major approaches may exist, neither of them being perfect. From one point of view, 
different depression subtypes may be results of different combinations of cognitive 
characteristics, personality traits and temperaments that coexist and interact in a temporal 
fashion in an individual with the environmental influences. These may have biological 
background, thus their genetic basis can be and has been, indeed, examined in association 
analysis of genetic main effect (e.g. genetic variants associated with rumination scores) or in 
GxE interaction analyses. Consistent results in these investigations may represent another 
subset of genes that could be tested in the search for novel antidepressants. From another 
perspective depression can also be decomposed based on symptoms. Different clusters of 
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symptoms may represent subtypes of the disease and may be investigated separately for 
genetic backgrounds. Even having only one of the two core symptoms, either marked loss of 
interest/pleasure or persistent sadness and low mood, represents different etiologies, the 
former being a lack of positive emotions, while the latter the appearance of negative 
emotions. Some propose different pathophysiological backgrounds for these two types of 
symptoms. Still, two patients manifesting each and only one of the core symptoms would both 
receive the same diagnosis of depression. Even more obvious differences exist between such 
symptoms of depression as insomnia and hypersomnia, decreased or increased appetite, 
psychomotor agitation or retardation. Furthermore, symptoms associated with depression may 
cluster based on a common etiological background and these clusters may lead to distinct 
clinical manifestations (Drevets et al., 2008). These different symptom-sets could also be 
investigated from a genetic angle, again ideally with the inclusion of GxE interactions (or 
even additional masking factors, like GxG or CNVs) resulting in another subset of genes for 
testing in preclinical models.   
 
None of these methods, however, are impeccable: 1) direct genetic variant-depression 
relationship is inconsistent, and so is GxE; 2) GxG, CNVs or rare variants lack current 
methodology or (usually) data for genome-scale investigations; 3) psychological traits and 
temperaments associate with many other diseases; 4) cognitive symptoms are characteristic of 
other severe disorders; and 5) symptom clusters do not necessarily represent true biological 
background. Still, these can be directions capable of revealing novel candidates that are 
desperately needed. Desperately needed, because almost all antidepressants still act on the 
monoaminergic systems that were proposed to be involved in depression by Coppen and 
Schildkraut in the 1960’s (Coppen, 1967; Schildkraut, 1965) and because results from animal 
depression models could not be translated into clinical success. As we will discuss, clinical 
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trials failed to provide convincing results with substances aiming at new targets. Therefore, 
we believe progress in the field can only be achieved by the better, finer understanding of 
underlying pathophysiology. This means that until then pharmacogenetic approaches are left 
to the optimization of current therapies. Consequently, in the last third of this review we 
provide an overview of pharmacogenetic studies aimed to unravel therapy failures and 
improve outcomes with currently applied agents. In these investigations the consideration of 
interacting genetic and environmental effects is similarly crucial in understanding treatment, 
as it seems that depression may respond differentially to treatment depending on whether 
there has been an environmental factor in the etiology (Keers and Uher, 2012). In addition, we 
propose another helpful approximation, which may bind current therapeutic effects and 
genetic variations in the form of different brain region activations demonstrated by imaging 
methods. We believe, as in the case of symptom clusters/temperaments for pathophysiology, 
this may represent an intermediate layer, where important results could be obtained, but this 
time for the optimization of already existing therapeutic approaches.  
 
In summary, we attempt to review the current state of the inherently complex field of 
depression and antidepressant genetics/genomics utilizing the complex, systems-based 
framework for pathophysiology shown in Figure 2. We do not aim for completeness, but 
besides providing a brief introduction we try to present evidence, raise problems and solutions 
for the different aspects from this unified point of view. While all of these reviewed 
approaches can be criticized as heterogeneous, fragmented and because they neglect certain 
aspects of the disease, clinical, biological or psychological relationships, we believe that only 
such a complex view on pathophysiology can decode depression and lead to efficient 
pharmacotherapy. 
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2. Genetic background of depression 
2.1 Genes with a main effect in depression  
Genetic variation explains a significant portion of the variance in depression. A large U.S. 
family-based study estimated the heritability of depression at 52% (Wang et al., 2017) and 
generally, estimates are in the range of 35-45% for general population samples which 
provides a profound evidence for a genetic basis (Kendler et al., 2006). Another estimate after 
detaching contextual effects such as shared environment and household report a smaller but 
still substantial heritability of 25% from a large U.K. population (Munoz et al., 2016). Single 
nucleotide polymorphism (SNP)-based heritability estimates (h
2
SNP) for depression were 
reported close to 10% (Cross-Disorder Group of the Psychiatric Genomics et al., 2013). 
However, the genetic contribution appears to be severity-dependent with 48-72% in hospital 
samples and 72% for severe, recurrent depression patients indicating that in certain subtypes 
of depression genetic contribution plays a more marked role (Sullivan et al., 2012; Uher, 
2014). Besides major depressive disorder (MDD) heritability, and especially the SNP-based 
heritability estimates, further indirect evidence for the pronounced genetic effects in 
depression has been provided by the significant gene and pathway-level results by enrichment 
methods (Network and Pathway Analysis Subgroup of Psychiatric Genomics, 2015), shared 
genetic factors (Purves et al., 2017), genetic correlations (rG), polygenic risk scores,  genetic 
sub-classification of depression (Yu et al., 2017), multivariate prediction of treatment success 
(Kautzky et al., 2015), and the shared genetics and epidemiological multimorbidity with other 
diseases (Marx et al., 2017). 
 
These heritability estimates and the ever-lower genotyping costs accelerated research 
that tried to unravel the implied genetic underpinnings of depression. In the last three decades 
research concerning the genetic background of depression has seen a vast increase, at first, 
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with a large number of association studies focusing on identifying candidate genetic variants. 
The assumptions behind the genes tested for simple pairwise statistical associations stemmed 
from our presumed knowledge of the neurobiology and neural systems involved in 
depression. During initial years, research focused on testing main effects of variants in major 
depression, which means that carriers of alleles or genotypes are more likely associated with 
the disease.  
 
A meta-analysis in 2008 reported that 393 genetic polymorphisms have been 
investigated in depression, with results published in 183 papers (Lopez-Leon et al., 2008). 
However, while replication is crucial in genetic studies, only 22 of the above 393 variants 
have been examined in at least three different studies, and could, therefore, be included in a 
meta-analysis. This meta-analysis supported a significantly elevated odds ratio for depression 
in case of APOE, GNB3 (C825T), MTHFR (C677T), SLC6A4 (40 bp VNTR, serotonin-
transporter-linked polymorphic region (5HTTLPR)), and SLC6A3 (44 bp Ins/Del), while 
found no significant effects in case of several other variants of genes repeatedly implicated in 
depression (HTR1A, HTR1B, HTR2A, HTR2C, TPH1, MAOA, COMT, BDNF, SLC6A2, 
DRD3, GABRA3 and ACE) (Lopez-Leon et al., 2008). Separately, some of these findings 
were supported, others debated by subsequent meta-analyses. For example, positive or 
partially positive associations were demonstrated for 5HTTLPR (Clarke et al., 2010; Kiyohara 
and Yoshimasu, 2010), MTHFR C677T (Wu et al., 2013), while negative results were 
obtained for BDNF Val66Met (Gyekis et al., 2013), SLC6A2 T-182C and G1287A (Zhao et 
al., 2013; Zhou et al., 2014), HTR2A rs6311 (Jin et al., 2013) and CLOCK polymorphisms 
(though the latter in the Japanese population; (Kishi et al., 2011)). 
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It was also demonstrated that these genes are non-specific to depression, with 1) the 
SLC6A4 polymorphism 5HTTLPR conferring risk for anxiety disorders, bipolar disorder, and 
depression, 2) SLC6A3 10-repeat variant (40bp VNTR) elevating chance for both ADHD and 
depression, and 3) MTHFR C677T polymorphism shared between schizophrenia, bipolar 
disorder and depression. Only GNB3 TT homozygote and APOE3 status showed elevated 
odds ratio specific for depression (Gatt et al., 2015). Most of the studies involving the above 
genetic variants, furthermore, had low sample sizes and faced replication issues. Analyses 
recruiting larger samples could not provide genetic validation for the candidate gene approach 
(Bosker et al., 2011; Wray et al., 2012) and indicated that most found associations were 
probably chance (false positive) findings (Flint and Kendler, 2014). While it cannot be 
excluded that some purely genetic factors, like e.g. those that may trigger mitochondrial 
dysfunctions can influence the development of the disease, these are non-specific for 
depression and rather mediate fundamental processes in mood regulation, cognition, etc. 
(Petschner et al., 2017). The dead-end of the candidate gene approach in revealing causal 
variants fostered the accumulation of more reliable genotypic information and larger clinical 
samples sparking the genome-wide association study (GWAS) and computational era of 
depression.   
 
2.2 Results of genome-wide association studies in depression 
To solve the problems of candidate gene association studies, GWASs tried to exceed their 
limitations. With large samples collected already, statistically significant genetic hits were 
rapidly accumulating for a wide range of psychiatric diseases but no replicable GWAS results 
were reported for depression as of 2014 (Flint and Kendler, 2014). Dunn et al (Dunn et al., 
2015) systematically reviewed 15 GWASes published before October 2013 conducted on 
major depressive disorder, depressive symptoms, or age at onset of depression. Popular 
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candidate genes (did not show any association, even though they were significant candidate 
genes in meta-analyses. Therefore, in accordance with Flint and Kendler (Flint and Kendler, 
2014), it seemed ever less compelling that these genes would play substantial, generalizable 
roles. Furthermore, the only genome-wide significant (GWS) hit in these 15 studies was the 
association of rs1545843 within SLC6A15 (Kohli et al., 2011). Despite its plausible action in 
depression as a neutral amino acid transporter, the association could only be replicated at a 
nominally significant level and in four of the five replication samples (Kohli et al., 2011). 
With these unconvincing results the authors remark that GWASs for depression lack 
environmental exposure as a variable and large enough samples (Dunn et al., 2015).  
 
Somewhat paradoxically, this relative lack of GWAS results combined with a priori 
(stemming from candidate gene approaches) information already implicated an essential 
insight into the genetic background of depression, namely, an upper bound for the genetic 
main effect strengths and consequently a polygenic architecture involving common variants 
with high population occurrence (minor allele frequencies or MAFs over 10%) and weak 
individual effects (odds ratios below 1.3) (Flint and Kendler, 2014).Remarkably, based on this 
polygenic model, depression genetics suggested a rather continuous risk for any person 
through the coincidental settings of myriads of common variants, just like blood pressure in 
hypertension risking stroke, with the only difference that sadness cannot be measured 
accurately (Sullivan, 2015). Another surprising, practical consequence, also recently receiving 
explicit confirmation (Mullins and Lewis, 2017) was that a significant proportion of the 
genetic background is stable behind depression subclasses, e.g. lifetime vs. severe forms or 
clinically established vs. self-reported, which could be used to achieve very large sample 
sizes, e.g. beyond 1 million, where sample size trumps accuracy (Major Depressive Disorder 
Working Group of the PGC. et al., 2017). A further stunning consequence of this model is 
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that 20% of the 18,000 genes expressed in the brain should be involved in the genetic 
architecture of major depression (Flint and Kendler, 2014). This substantial genetic 
contribution is independent of further specialties of depression with respect to other 
psychiatric diseases, such as the relatively high prevalence, high heterogeneity and high 
environmental dependency of depression, however, these depression specificities may give 
further explanations for the lack of results below a critical GWAS sample size (Levinson et 
al., 2014). 
 
Equipped with this knowledge, after reaching critical study designs in GWASs, this 
much expected voluminous set of weak factors recently started to become statistically visible, 
providing at least testable hits (Cai et al., 2015; Major Depressive Disorder Working Group of 
the PGC. et al., 2017; Mullins et al., 2016). Several GWAS studies have been published with 
large sample sizes and on various measurements of the depression phenotype. Table 1 
provides an overview of these recent findings within each study, and the discovery and 
replication samples, also underscoring the overlap in them.  
 
Besides internal replications from the above results only three replicated between 
different studies (Table 2). The presynaptic cytomatrix protein piccolo (PCLO) gene proposed 
originally (but remained non-significant) by Sullivan in 2009 (Sullivan et al., 2009) became a 
GWS hit in the work of Mbarek et al. and could be replicated by Wray et al. (but only with 
gene-based analysis, not on variant level) (Mbarek et al., 2017; Wray et al., 2012). The 
polymorphism rs12552 of olfactomedin 4 (OLFM4) seems to be the only SNP currently 
replicated in two separate GWASs (with overlapping populations) and different SNPs showed 
genome-wide significant (GWS) hits in neuronal growth factor regulator 1 (NEGR1) in the 
Hyde- and Wray-studies. 
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In summary, despite enormous sample sizes, replicability of GWS findings in 
independent samples could not be reliably achieved and even large-scale GWASs fail to 
replicate each other’s findings in addition to the unsuccessful internal replications. These 
problems, thus, still leave a considerable gap in our understanding of the genetic contributions 
that can be related to the unique feature of depression among psychiatric diseases: to the well-
known, strong influence of environmental factors. 
 
3. The role of environment in the development of depression  
Besides genetic factors depression heavily depends on environmental influence. A recent 
study in more than 2 million offspring from the Swedish Extended Adoption Study has 
proven that genetic factors and rearing experiences contribute equally to depression risk in 
parent-offspring transmission (Kendler et al., 2017) providing strong evidence for a 
significant, large role of environmental stressors. In further support, antecedent chronic and 
acute stressors associated significantly with depression in women, stressors were 2.5 times 
more likely in depressed than controls and around 80% of depression cases had life events in 
anamnesis (Hammen, 2005; Hammen et al., 2009). Diverse environmental factors have been 
connected through evidences to depression and in Table 3 we collected the most important 
findings according to reviews from the past few years categorizing them into life stages 
(Schmitt et al., 2014).  
 
Before concluding that environment-driven depression is a common phenomenon, it is 
worth to note the marked difference between stressors and depression: whereas the total 
prevalence of the heterogeneous stressors is common, e.g. frequency of severe life events is 
estimated to be one in every 3–4 years, depression is triggered in only about 20% of those 
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with acute stress exposure (Brown et al., 1987). In addition, we would like to point out again 
to the already discussed study showing aggregation of family cases in those exposed to 
environmental stress, where the authors hint that vulnerability towards stress and 
environmental influences may be dependent on the genetic background (Kendler and 
Karkowski-Shuman, 1997). All these results suggest complex interactions of the genetic 
background with these stress factors and their synergistic or interaction effects on depression 
(Lopizzo et al., 2015).   
 
3.1 Concept of gene-environment interaction studies and evidence for their role in 
depression 
The seminal GxE study on depression was published in 2003 showing that the short (S) allele 
of 5HTTLPR polymorphism in the promoter region of serotonin transporter gene (SLC6A4) 
interacts with stressful life events and childhood maltreatment to affect depression (Caspi et 
al., 2003). This study generated interest in the field and many researchers conducted 
replication studies resulting in large enough populations for meta-analyses that showed mixed 
results. Three meta-analyses could demonstrate positive interactions (Bleys et al., 2018; Karg 
et al., 2011; Sharpley et al., 2014), while other three could not replicate original findings 
(Culverhouse et al., 2018; Munafo et al., 2009; Risch et al., 2009) (Table 4). It is important to 
use deep-phenotyped samples in GxE studies, because particular and often neglected factors 
can further strongly affect findings. For example a study demonstrated an interaction between 
5HTTLPR and financial difficulties but not other types of stress on depression (Gonda et al., 
2016).  
 
Brain-derived neurotrophic factor (BDNF) is another example often investigated in a 
GxE setup. Two meta-analyses confirmed the significant GxE effect on depression between 
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BDNF Val66Met polymorphism and life stress (Hosang et al., 2014; Zhao et al., 2017), one of 
them highlighting that results were stronger in the case of stressful life events, but only a 
statistical trend was found with childhood adversity (Hosang et al., 2014).  Besides 
5HTTLPR, other monoaminergic genes have frequently been tested. Polymorphisms in MAOA 
encoding monoamine-oxidase A playing a role in serotonin, noradrenaline and dopamine 
catabolism interacted with childhood maltreatment and maternity difficulty affecting 
depression (Mandelli and Serretti, 2013; Naoi et al., 2017; Uher, 2014), although at least four 
studies presented negative results (Mandelli and Serretti, 2013), therefore, the role of MAOA 
in GxE studies of depression remains, at best, questionable. COMT encoding catechol-O-
methyltransferase involved in the metabolism of noradrenalin and dopamine interacted with 
several forms of stressors showing a more consistent role in modulating environmental effect 
on depression (Mandelli and Serretti, 2013). SLC6A2 encoding noradrenaline transporter 
which reuptakes noradrenalin from synaptic clefts showed an interaction effect with severe 
stressful life events and rural living among women on depression (Mandelli and Serretti, 
2013).  Some variants of HPA axis genes have also been investigated in GxE interactions for 
depression. FKBP5 interacted with childhood trauma and stressful life events; and 
corticotropin-releasing hormone receptor 1, CRHR1 with childhood maltreatment predicting 
depression, although the latter gene showed mixed results in subsequent studies (Mandelli and 
Serretti, 2013). A novel study (Gonda et al., 2017) identified an interaction between GABRA6 
and stressful life events in depression.  
 
Inflammation as a result of chronic stress has also been proposed in depression 
etiology (for a review see (Kiecolt-Glaser et al., 2015). Such a connection was supported by 
some GxE studies – for example IL1B and IL-6 interacted with several stress factors (stressful 
life events, childhood maltreatment, chronic interpersonal stress) in the background of 
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depression (Baumeister et al., 2016; Kovacs et al., 2016a; Kovacs et al., 2016b; Tartter et al., 
2015).  Genes of the galanin (a stress-inducible neuropeptide) system have also been proposed 
as important mediators of stress effects in depression (Juhasz et al., 2014) suggesting that 
GALR1 and GALR3 possibly exert their modulating effect through childhood maltreatment, 
while GALR2 through recent stressful life events.  Another interesting target in GxE studies of 
depression is the endocannabinoid system due to its role in recovery from stress (Lazary et al., 
2009). CNR1 (cannabinoid receptor 1 gene) showed interaction with stressful life events and 
physical abuse (Juhasz et al., 2009; Mandelli and Serretti, 2013), although further proof is 
needed to elucidate its role in the pathogenesis of depression. A study also identified an 
interaction between FAAH (encoding fatty acid amide hydrolase which is responsible for 
anandamide degradation) and childhood maltreatment to associate with depression (Lazary et 
al., 2016). Multiple other genes have been tested with highly mixed or negative results in GxE 
studies of depression. Instead of elaborating these we focused here on main findings from 
such investigations and also on other lesser known variants or interactional findings with 
multiple environmental factors.  
 
3.2 Interaction with stress in depression GWAS studies  
To date, two studies have assessed GxE effect on a genome-wide scale (genome-wide gene-
environment interaction study, GWEIS) with childhood trauma on depression. In one of them 
(Van der Auwera et al., 2018), to test these GxE effects on depression in 3944 European 
subjects, the GWEIS approach was combined with a candidate gene analysis to obtain a 
proper power, choosing candidate genes based on two reviews and former GWAS results. No 
GWS hits emerged, and the authors also did not find consistency between the different 
analytic approaches leading them to suggest the need for larger samples (Van der Auwera et 
al., 2018). The other study conducted a GWAS on depression in 203 patients and 193 controls 
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from a Mexican American cohort, both groups having significant hyperactivation of the HPA 
axis related to distress and acculturation issues (Wong et al., 2017a). Their results revealed 44 
common and rare functional variants in the Mexican American sample, but only the rare 
variant analysis came to a successful replication in a European cohort: it replicated the 
association of PHF21B (PHD finger protein 21B) gene. 
 
Further two GWEIS studies have been performed on CES-D (Center for 
Epidemiological Studies-Depression) depression scale, seeking the interaction of genetic 
variants with stressful life events within the previous one year. Dunn et al. investigated this 
interaction in 7179 African American and 3138 Hispanic American postmenopausal women 
from the WHI (Women’s Health Initiative). They found one GWS GxE signal in African 
Americans, rs4652467 near CEP350 (centrosomal protein 350) gene, but it could not be 
replicated in 1231 African American women from the HRS (Health and Retirement Study) 
and 2010 African American women from the Grady Trauma Project (using the Beck 
Depression Inventory to measure depression) (Dunn et al, 2016). The other study on recent 
life stress and CES-D (Otowa et al., 2016) was conducted in 320 Japanese subjects and found 
only a marginally significant GxE finding, the rs10510057 near RGS10 (regulators of G-
protein signaling 10) gene.  
 
3.3 Summary of GxE investigations in depression 
While GxE studies provide the opportunity to have a better characterization (and 
additional evidence) of genes with previously identified roles in a disease, and also to identify 
new genes with (only) environment-dependent effects, they also make it possible to determine 
the type of risk environments that may facilitate disease development, and also to find 
protective effects (Mandelli and Serretti, 2013). Although candidate GxE studies have a better 
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replicability record, results remain inconclusive which can be understood by the larger 
expected sample size corresponding to potential environmental context-specific GxE 
interactions and the high variability of the distributions of environmental stressors in different 
populations. Only the stratification for these potential environmental factors without their 
explicit inclusion in the analysis could hypothetically decrease the variability of the results 
and improve replicability. However, measuring all these environmental factors, which have 
substantially different distributions in the population (for example childhood 
maltreatment/abuse being intuitively rarer than recent life events that are experienced by all 
individuals) poses a significant problem (see Table 3 that listed some of the environmental 
risk factors for depression.). 
 
 Despite the problems the field faces, GxE investigations in depression are important 
exploratory tools in the search for novel candidates. In fact, they already provided some of the 
testable markers awaiting confirmation and replication. Unfortunately, the studies (especially 
candidate gene studies) often use very small sample sizes that are inadequate to draw decisive 
conclusions. As a final remark, we have to note that in addition to GxE interactions, other 
candidates to provide novel targets are abundant and include CNVs (Flint and Kendler, 2014; 
Levinson et al., 2014), rare variants, GxG and ExE interactions.   
 
4. Other directions: Rare variants, CNVs, GxG, ExE and higher-order interaction 
combinations in association with depression 
Rare variants (with MAF<0.01) remained unfeasible to investigate, especially because of the 
common variant-common disease hypothesis, although a few studies yielded results. 
Altogether 11 rare (MAF<0.01 in the control population) variants were associated with 
depression in the already mentioned GWAS study of Wong et al. in a Mexican-American 
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cohort, although it must be noted that participants were also exposed to environmental stress 
(Wong et al., 2017a, 2017b). A GWS missense mutation was demonstrated in the LIPG gene 
on chromosome 18 in an investigation for depressive symptoms in an elderly sample (Amin et 
al., 2017), and variants in LHPP and CPXM2 genes were also suggested to be risk factors for 
depression in Mexican-Americans (Knowles et al., 2016). A gene set including STXBP5, 
RIMS1, CTNNB1, DMXL2, SYN1, YWHAB, YWHAH genes was found to be significantly 
enriched in European-American early-onset depression cases in a rare variant analysis 
(Pirooznia et al., 2016), while both F528C in SLC6A2 and R219L in HTR1A showed 
associations with depression in a German sample (Haenisch et al., 2009). Other approaches 
also yielded some results. Rare diseases, like Huntington’s disease, acute intermittent 
porphyria, Wolfram syndrome or mitochondrial disorders are often accompanied by 
depression or depressive symptoms mostly in addition to severe other impairments (Berrios et 
al., 2002; Perlis et al., 2010b; Petschner et al., 2017; Smoller, 2016). In case of diseases with 
cognitive involvement, like Huntington’s disease, mood disorders can precede the onset of the 
primary disease with decades. However, the possibility of rare variants causing exclusively 
depressive symptoms with no manifestation of Huntington’s disease was also raised for the 
CAG repeats in the huntingtin gene (Perlis et al., 2010b). Such possibilities are hard to 
exclude, because investigations into major depressive disorder enroll younger patients and 
follow-up is often limited and restrict determination of disease manifestation with later onset.  
 
A GWAS, applying another approach, examined structural CNVs in relation with 
depression. Duplication of a sequence near SLIT3 has been identified by Glessner et al. 
(Glessner et al., 2010) which found partial confirmation in another family-based study that 
identified mutations in the SLIT3 among patients of autism spectrum disorders showing 
depressive symptoms (Cukier et al., 2014). In recurrent depression copy number deletions 
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were also detected but remained unsupported by a re-analysis (Rucker et al., 2016; Rucker et 
al., 2013). In summary, while depression cases without rare disease comorbidity are probably 
not substantially influenced by rare variants, rare and structural variations may mask some 
patient populations and interfere with GWASs and GWEISs results, especially, because these 
variants are often excluded in initial quality control steps (see e.g. protocol of (Coleman et al., 
2016)), but in fact, regardless of exclusion they may be causal in phenotype variation and 
distribution in the background. Their inclusion into the analysis, therefore, would be more 
than welcome. Even better would be to filter healthy individuals carrying known mutations, 
thus, more homogeneous genetic samples were to be analyzed. On the other side, even 
Mendelian diseases not necessarily manifest in carriers of penetrant mutations (Chen et al., 
2016), which lead us to another well-known phenomenon, GxG interactions.  
 
GxG interactions are equally promising candidates as GxE interactions (Gage et al., 
2016; Taylor and Ehrenreich, 2015) and were mostly performed on candidate genes. Linkage 
analysis pointed to a possible interaction of 5HTTLPR with an unknown gene on 
chromosome 4 (Neff et al., 2010). MTHFR A1298C polymorphism was shown to interact 
with COMT Val158Met with homozygous CC carriers and COMT Met carriers having 
elevated risk, especially in women according to two studies (Nielsen et al., 2015). 
Polymorphisms interacting within the CRHR1 and AVPR1b genes may also underlie 
depression susceptibility (Szczepankiewicz et al., 2013) but could not be replicated for 
depression after suicide attempts (Ben-Efraim et al., 2013), while by investigating other 
polymorphisms in CRHR1 an interaction was also demonstrated with BDNF Val66Met 
polymorphism in a Chinese sample (Xiao et al., 2011). Less obvious candidates were also 
investigated. In a small, heterogeneous sample depression diagnosis was influenced by 
polymorphisms in matrix-metalloproteinase (MMP) genes, but effect depended on the carrier 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
status of polymorphisms examined (Bobinska et al., 2016). BCL1 rs41423247 and the 
CHRNA4 rs1044396 were also shown to interact on current depression scores in a nonclinical 
sample of 800 (Reuter et al., 2012) and TAAR6 and HSP-70 also could influence each other’s 
effect on a Korean sample for both depression and bipolar disorder, though small sample size 
may have distorted results (Pae et al., 2010).  
 
However, as in the case of main effect analyses, the only large study conducted to our 
knowledge could not confirm candidate GxG findings on 4,824 cases and 36,162 controls and 
978 cases and 2,992 controls as replication. While no GWS hits (in this case p-value<10
-12
) 
were demonstrated for pairwise GxG interactions in logistic regressions, nominally significant 
interactions were found between 1) rs16912862 (ZNF169) and rs4769180, 2) rs7587468 and 
rs13120959 (PRSS12), 3) rs2651975 (TMCC3) and rs9940287 and 4) rs6414384 (KCNAB1) 
and rs10843021, according to the two applied methods and with 2) and 4) replicated (Murk 
and DeWan, 2016). Thus, like in the case of main effect analyses, candidate gene approaches 
and large, genome-wide approaches yield no overlapping results, even if we consider the 
found results valid, which is often debated due to sample sizes. Additionally, we already cited 
research demonstrating that genes without any main effect may also contribute to GxG 
interactions (Culverhouse et al., 2002) and also discussed the concept of GxE interactions that 
may also contribute to different interpretation of GxG interactions expanding the possibilities. 
 
While interaction between genes seems to be plausible, less well explored are ExE 
interactions. To briefly discuss the concept of ExE interactions we only bring one example. 
Evidence suggests that experienced stress in adolescence may mediate the connection 
between early adversities and onset of depression (Shapero et al., 2014). In our European non-
clinical sample of more than 2000, those exposed to both childhood abuse and lifetime 
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negative life events had a disproportionately higher likelihood ratio for lifetime depression 
than having only one of the stress factors in their life (unpublished data).  Three-way 
interactions are also possible. GxGxE interactions were demonstrated especially after a 
combined BDNF Val66Met and 5HTTLPR influence on amygdala and subgenual portion of 
anterior cingulate connectivity was proven in 2008 (Pezawas et al., 2008). The S carrier status 
was a risk factor in the presence of Val/Val genotype after childhood abuse (Grabe et al., 
2012) but elevated risk for depression was found in 5HTTLPR S and BDNF Val66Met Met 
carriers and family environment in a longitudinal youth sample (Dalton et al., 2014). Authors 
reviewing evidence on the topic concluded that the interaction between BDNF Val66Met and 
5HTTLPR may involve epigenetic regulating mechanisms triggered by environmental stress 
(Ignacio et al., 2014). BDNF Val66Met polymorphism was the center of another GxGxE 
investigation yielding positive results with GSK3B and recent life events in a Chinese sample 
(Yang et al., 2010).  ExExG interactions are also plausible opportunities, as demonstrated for 
the dependency of 5HTTLPR effects on both recent life event and childhood abuse exposure 
on a multivariate phenotype including lifetime depression, depression and anxiety scores in 
young (Juhasz et al., 2015).  
 
Even higher order interactions may be possible, as in the case of the BDNF Val66Met  
polymorphism showing significant 5-way interactions with four different polymorphisms, 
though all from within the NTRK2 gene in a geriatric clinical sample (Lin et al., 2009).  From 
a genome-wide perspective higher order (but even GxG) investigations require new methods 
coping with interaction that can be scaled-up both statistically and computationally. 
Unfortunately, currently available tools handling two-way, but especially higher-order 
interactions cannot be easily (or at all) scaled-up to the genome-wide level (see e.g. (Moore et 
al., 2017; Musani et al., 2007; Wright et al., 2016)). A promising direction is the incorporation 
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of background knowledge into machine learning methods exploring interactions in the future 
(Ritchie et al., 2017).  In light of the results, it may seem tempting to conclude that endless 
possibilities exist and that even higher-order interactions may represent the future in the 
genetic research of depression. While they may be, indeed, an interesting opportunity, all the 
above candidate gene studies can best be regarded as pilot investigations, because of their 
highly limited sample sizes. Especially, higher order interaction analyses lose rapidly on 
power, on one hand, because considering the already discussed ExE interaction, very few 
individuals will be included in a given group of patients. However, because of similar 
considerations, in case of true non-random distribution of alleles, results may be highly 
inflated. Additional investigations are required with adequate sample sizes to secure the place 
for such interactions in the genetic analyses for depression.  
 
5. Unmet needs of currently available antidepressive medications: Pharmacogenomics 
approaches 
On the contrary of the huge variability of genes with possible pathophysiological roles (see 
Table 5), all current antidepressant medications influence monoaminergic systems. This 
mechanism of action comprises reuptake inhibition, a decrease in monoamine metabolism and 
manipulation of pre- or postsynaptic receptors. The oldest classes of antidepressants were the 
tricyclic antidepressants (TCAs) and monoaminoxidase inhibitors (MAOIs). As a results of 
their relatively abundant side effects, more selective substances, like selective serotonin 
reuptake inhibitors (SSRIs), selective serotonin and noradrenaline reuptake inhibitors 
(SNRIs), noradrenaline/dopamine reuptake inhibitors (NDRIs), noradrenaline reuptake 
inhibitors (NRIs), in addition to noradrenergic and selective serotonergic antidepressants 
(NaSSAs) and serotonin antagonist and reuptake inhibitors (SARIs) were developed. While 
these are more selective towards their molecular targets than TCAs, this selectivity manifests 
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only in better side effect profiles, not better efficacy. And efficacy remains sobering. Just one 
third of patients experience attenuation of depression symptoms after first treatment and only 
two thirds of patients show remission after four treatment trials, while altogether 10% of 
patients do not react to any of the available treatments even after multiple attempts (Crisafulli 
et al., 2011; Rush et al., 2006; Trivedi et al., 2006). Consequently, quality life years and huge 
costs go wasted, thus, the need for better therapies, like drugs with novel mechanisms of 
action and the optimization of current therapeutic approaches, remains enormous.  
 
However, according to completed clinical trials, substances with novel mechanisms of 
action, like those with ketamine-like NR2B antagonistic, tramadol-like opioidergic, p38 
mitogen-activated protein kinase inhibitor or CHRH1 antagonistic properties consistently 
failed to show long-term therapeutic antidepressant effects in adults (Ibrahim et al., 2012; 
Richards et al., 2016) (Clinical trials: www.clinicaltrials.gov; NCT00472576; NCT00986479; 
NCT01482221; NCT02014363). These results suggest that investigators are rather left to 
optimize current therapeutic approaches than obtaining novel ones in the near future.  
 
One obvious choice for such optimization was the field of pharmacogenetics or the 
broader field of pharmacogenomics. The term pharmacogenetics marks ’clinically important 
hereditary variation in response to drugs’ as defined by Vogel in 1959 (Vogel, 1959), while 
pharmacogenomics is the extension of this concept into a genome-scale scope. Variations in 
medication response may be divided into two main areas. First, inherited variation in the 
resorption, distribution, metabolism and excretion of drugs called comprehensively 
pharmacokinetics results in altered drug concentrations at the site of action. Second, variation 
in the molecules directly implicated in the effects antidepressants may cause altered direct 
response of these medications and is referred to as inherited variation in the 
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pharmacodynamics of antidepressants. The foremost aim of precision and personalized 
medicine is the identification of genes involved behind pharmacokinetic and 
pharmacodynamic variation of treatment response to antidepressants and by selectively 
matching patients and appropriate therapies based on this information, to improve outcomes.  
 
5.1 Pharmacogenetic studies of pharmacokinetic variation of antidepressants 
Among the distribution, metabolism and excretion of ADs two processes deserve 
distinguished attention: distribution and metabolism. Distribution is special because 
antidepressants act in the brain and have to penetrate the blood-brain barrier (BBB). Evidence 
supports the notion that genetic polymorphisms in the ABCB1 transporter gene (P-
glycoprotein, MDR1), a member of ATP-binding cassette superfamily of membrane transport 
proteins (Schinkel et al., 1994), may influence therapeutic efficacy through efflux transport in 
the BBB and, thereby, lower concentrations of antidepressants in the brain (Peters E. J. et al., 
2009). Studies have shown influence of single-nucleotide polymorphism carrier status on 
therapeutic outcomes after antidepressant treatment with substrates of the ABCB1 
(Breitenstein et al., 2014), while such effects with non-substrates of ABCB1 were lacking 
suggesting true influence (Laika et al., 2006; Mihaljevic Peles et al., 2008; O'Brien et al., 
2013; Perlis et al., 2010a; Peters et al., 2008). However, some contradictory findings also 
emerged and point to the need for further studies (Fukui et al., 2007; Gex-Fabry et al., 2008). 
In summary, ABCB1 polymorphisms seem to be able to affect therapeutic outcomes of 
antidepressants.  
 
The cytochrome P450 (CYP) enzymes are hepatic hemeproteins responsible for first 
phase drug metabolism. Several lipophilic substances, including antidepressants, are 
metabolized by CYPs. The genes encoding these enzymes are highly polymorphic and in the 
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population people have different metabolizing capabilities and altered metabolism rates can 
result in altered drug plasma concentrations (Wolf and Smith, 1999). The metabolism of 
antidepressants occurs mainly through CYP2D6, CYP2C9, CYP2C19, CYP3A4 and CYP1A2 
isoenzymes (Crisafulli et al., 2011; Spina et al., 2008). CYP2D6 metabolizer status can be 
poor, intermediate, extensive and ultrarapid (PM, IM, EM, UM, respectively) and similar 
classification is also common for other CYP enzymes. From a pharmacokinetic perspective 
drug plasma levels associated consistently with metabolizer status with PMs and IMs showing 
higher levels of antidepressants and UMs having lower plasma levels for substrates of 
CYP2D6, CYP2C9 and CYP2C19 (Altar et al., 2013). However, association with treatment 
response was less clear cut. Only four from ten studies that investigated antidepressant 
response in association with CYP2D6 metabolizer status showed significant association while 
CYP2C19 and CYP2C9 metabolizer status and therapeutic response remained uninvestigated 
by the review of Altar and colleagues (Altar et al., 2013). Indecisive results were obtained by 
Müller and colleagues providing mixed results for the association of metabolizer status and 
treatment response with various antidepressants in their review (Muller et al., 2013). To 
specify, a study has shown that paroxetine was less effective in CYP2D6 EMs (Gex-Fabry et 
al., 2008), while escitalopram and citalopram were more effective in IMs for CYP2D6 and 
CYP2C19 (Mrazek et al., 2011; Tsai et al., 2010). In sum of the two reviews, overall 62.5% 
of studies showed association with metabolizer status and antidepressant adverse events in by 
Altar et al. and a modest association between adverse events and metabolizer status of various 
CYP enzymes was also supported by Müller et al. (Altar et al., 2013; Muller et al., 2013). At 
the same time, Crisafulli and colleagues conclude that data regarding the importance of CYP 
genotypes in AD effects remains inconclusive  with both positive and negative results 
(Crisafulli et al., 2011).  
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The discrepancies may be explained in light of the complexity of the metabolic 
pathways. Most of the metabolic routes of a given drug are redundant and in case of lower 
activity of a given CYP enzyme (which may be through an inherited PM status), other 
enzymes may contribute more intensively. Therefore, one might argue, a more complex 
approach that considers all possibly relevant CYP polymorphisms may reveal composite 
phenotypes in which these polymorphisms could influence therapeutic efficacy. However, 
even these approaches failed to be consistent. An approach creating a composite phenotype 
using 44 alleles in CYP2D6, CYP2C19, CYP1A2, SLC6A4, and HTR2A (the latter two 
belonging to pharmacodynamics) genes could prove an association in a combined population 
of 258 patients for clinical response, but not for remission rates (Altar et al., 2015). Another 
study indicated that the inclusion of pharmacogenetics based on CYP genes (CYP2D6, 
CYP2C9, CYP2C19 and CYP3A4/5) could have a positive impact on therapeutic response to 
antidepressants (Torrellas et al., 2017). Another systematic review included 2 randomized 
clinical trials, 5 cohort studies and 6 modelling studies and found that ABCB1 genotyping and 
CNSDose based genotyping (based on ABCB1, ABCC1, CYP2C19, CYP2D6, UGT1A1 genes) 
could also improve response (Breitenstein et al., 2016; Peterson et al., 2017; Singh, 2015; 
Winner et al., 2013). At the same time routine screening for these genotypes is not 
recommended by the authors (Peterson et al., 2017). Despite the separated plasma 
concentrations and therapeutic efficacies most articles conclude that CYP metabolizer and 
ABCB1 status can be an important influencing factor of antidepressant efficacy (Torrellas et 
al., 2017). Such genotyping, however, is rather valid in case of side effects, where more 
conclusive results are found, though not without contradictions (Altar et al., 2013; Crisafulli 
et al., 2011; Horstmann and Binder, 2009). As a summary, while ABCB1 polymorphisms 
seem to consistently influence antidepressant efficacy, CYP enzymes and metabolizer statuses 
require more complex approaches and their roles remain unconvincing.  
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5.2 Pharmacogenetics of antidepressant pharmacodynamics 
Most pharmacogenetics studies on antidepressant treatment response investigated 
monoaminergic candidate genes with the highest attention to the serotoninergic system as a 
result of the proven mechanism of action of antidepressants.  Among serotonergic genes, 
SLC6A4 is one of the most widely studied candidate genes of antidepressant treatment 
response. 5HTTLPR besides having two alleles (Heils et al., 1996), through SNP rs25531 can 
also be regarded as a triallelic polymorphism (Praschak-Rieder et al., 2007) with possible 
impact on treatment outcome via increased gene expression in A allele carriers at the latter 
(Manoharan et al., 2016). Meta-analyses showed better antidepressant treatment response and 
remission rates with the L and L(A) carriers (Porcelli et al., 2012; Serretti et al., 2007). 
However, findings are divergent with one meta-analysis and several previous studies showing 
no association between 5HTTLPR and treatment response (Andre et al., 2015; Dogan et al., 
2008; Perlis et al., 2010a; Poland et al., 2013; Taylor et al., 2010). Another polymorphism, a 
variable number tandem repeat (VNTR) in the intron2 of SLC6A4 implicates enhanced 
expression in individuals with longer repeats (Murphy and Moya, 2011) and meta-analysis 
also confirmed better response to antidepressant treatment expressed mostly in Asian patients 
with the 12/12 genotype (Kato and Serretti, 2010; Niitsu et al., 2013). However, reported 
results are puzzling as a number of studies reported contradictory results (Dogan et al., 2008; 
Ito et al., 2002; Smits et al., 2008; Weinshilboum, 2009; Wilkie et al., 2008). 
 
Besides 5HTTLPR, serotonin receptor-encoding genes were also extensively studied, 
especially HTR1A and HTR2A. Although a promoter polymorphism in HTR1A gene has been 
associated initially with antidepressant treatment response (Hong et al., 2006; Villafuerte et 
al., 2009; Yu et al., 2006), recent studies contradict these findings (Antypa et al., 2013; Basu 
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et al., 2015; Dong et al., 2016; Kato et al., 2009; Serretti et al., 2013; Zhao et al., 2012a). 
Moreover, three meta-analyses found no significant effect on antidepressant side effects or 
treatment response (Kato and Serretti, 2010; Niitsu et al., 2013; Zhao et al., 2012b). 
Concerning other less widely studied polymorphisms in the HTR1A gene findings are 
similarly less decisive (Chang et al., 2014; Kato et al., 2009; Yu et al., 2006). The A allele of 
the intronic polymorphism in rs7997012 HTR2A has been associated with better outcome to 
antidepressant treatment in the Sequenced Treatment Alternatives to Relieve Depression 
(STAR*D) study (McMahon et al., 2006). Consequently, the gene has been widely 
investigated but, again, with heterogeneous results. Despite some supporting evidence (Kishi 
et al., 2010; Peters Eric J. et al., 2009), a number of studies reported an inverse allelic 
association (Antypa et al., 2013; Lucae et al., 2010) or no association (Hong et al., 2006; Illi 
et al., 2009; Perlis et al., 2009; Rhee-Hun et al., 2007; Sato et al., 2002; Serretti et al., 2013; 
Staeker et al., 2014; Zhi et al., 2011) with treatment response, whereas meta-analyses reported 
mixed results (Lin et al., 2014; Niitsu et al., 2013). Other polymorphisms in HTR2A, like 
rs6311 (Choi et al., 2005; Kato et al., 2006; Kishi et al., 2010) and rs6313 (Kautzky et al., 
2015; Kishi et al., 2010; Noordam et al., 2015) also associated with antidepressant response 
but meta-analyses (Kato and Serretti, 2010; Lin et al., 2014; Niitsu et al., 2013) and a plethora 
of previous studies (Basu et al., 2015; Dong et al., 2016; Hong et al., 2006; Illi et al., 2009; 
Qesseveur et al., 2016; Rhee-Hun et al., 2007; Zhi et al., 2011) showed mixed or 
contradictory results. The influence of other variants within the gene remains similarly 
controversial through the lack of wide-scale replications (Kishi et al., 2010; Lucae et al., 
2010; Qesseveur et al., 2016; Tiwari et al., 2013; Uher et al., 2009). 
 
Three metabolic enzymes, MAOA, COMT, and TPH, were investigated for their roles 
in antidepressant response. The VNTR in the promoter region of MAOA has been associated 
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with better treatment outcome in individuals carrying the short form (Tzeng et al., 2009), but 
results were mostly restricted to female patients (Domschke et al., 2008a; Yu et al., 2005). 
Regarding other variants within the MAOA gene, including rs1465108, rs6323 and rs1799835, 
findings are not clear since studies reported either no association (Leuchter et al., 2009; Peters 
Eric J. et al., 2009) or associations only in females (Tadic et al., 2007). The COMT rs4680 
polymorphism has been suggested to influence antidepressant treatment response but there is 
a big discrepancy regarding which genotype is more advantageous. First studies reported the 
Val allele to be associated with better outcome (Arias et al., 2006; Szegedi et al., 2005), later, 
various studies reported opposite allelic association (Baune et al., 2007; Benedetti et al., 2009; 
Benedetti et al., 2010; Spronk et al., 2011; Tsai et al., 2009; Yoshida et al., 2008), or even no 
significant association with treatment response (Kautzky et al., 2015; Kocabas et al., 2010; 
Leuchter et al., 2009; Serretti et al., 2013; Taranu et al., 2017), with a meta-analysis also 
failing to confirm any impact (Niitsu et al., 2013). From the two isoforms of TPH, attention 
focused on a polymorphism within TPH1 (Ham et al., 2007; Viikki et al., 2010). However, 
most studies on rs1800532 could not confirm the role of this polymorphism in antidepressant 
efficacy (Ham et al., 2005; Illi et al., 2009; Kato et al., 2007; Kim et al., 2014; Uher et al., 
2009; Wang et al., 2011) and meta-analyses again failed to provide decisive conclusions 
(Kato and Serretti, 2010; Niitsu et al., 2013; Zhao et al., 2015). 
 
Genes influencing glutamatergic neurotransmission have also been implicated in 
therapeutic response to antidepressants. An association between rs1954787 in ionotropic 
glutamate kainate 4 receptor (GRIK4) gene and citalopram response have been reported in the 
STAR*D study (Paddock et al., 2007). Despite some negative findings (Horstmann et al., 
2010; Perlis et al., 2010a; Serretti et al., 2012), subsequent meta-analysis confirmed the 
relevance of rs1954787 in antidepressant treatment outcome (Kawaguchi and Glatt, 2014), 
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furthermore some studies showed associations with other GRIK4 polymorphisms too 
(Horstmann et al., 2010; Milanesi et al., 2015), but further studies are still needed. 
 
The most investigated polymorphism of BDNF (brain derived neurotrophic factor), 
involved in neuroplasticity and showing lower levels in depressed patients and an increase 
following antidepressive or electroconvulsive therapy (Brunoni et al., 2008), is rs6265 
(Val66Met). Meta-analyses showed the involvement of rs6265 in antidepressant treatment 
response and remission (Kato and Serretti, 2010; Niitsu et al., 2013; Yan et al., 2014) and 
some recent studies supported these results (Colle et al., 2015; Murphy et al., 2013). Despite 
these promising findings, numerous studies reported again no association (Katsuki et al., 
2012; Li et al., 2013; Matsumoto et al., 2014; Musil et al., 2013; Yoshimura et al., 2011). One 
study found another SNP within the BDNF gene to be associated with treatment response, 
however, this result could not be replicated in other samples (Domschke et al., 2010a).  
 
In the gene encoding the FK506-Binding Protein 51 (FKBP5), involved in the 
modulation of glucocorticoid receptor (GC) sensitivity and considered as a regulator of stress 
response (Binder, 2009), three polymorphisms, rs1360780, rs3800373 and rs4713916, have so 
far been associated with antidepressant treatment response (Binder et al., 2004) and findings 
are confirmed by meta-analyses (Niitsu et al., 2013; Zou et al., 2010). Still, unequivocal 
conclusions are again lacking because various studies found no association (Perlis et al., 2009; 
Sarginson et al., 2010; Uher et al., 2009).  All these results provide an evidence for the 
complexity and contradictions in the field.  
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5.3 Pharmacogenomics of antidepressants: Moving from candidate gene studies to GWASs 
Since candidate gene studies remain heterogeneous, the recent surge in available genotyping 
data and methodological development fostered the extension of association studies from 
individual genes onto the genome-wide level also in the field of efficacy of antidepressants. 
Genome-wide association studies (GWASs) associating single-nucleotide polymorphisms on 
the whole genome to antidepressant response represent a hypothesis-free approach to the 
problem and theoretically, could reveal polymorphisms which were left out so far because of 
lack of evidence.  
 
In line with pharmacokinetic results from candidate gene studies, Ji et al. provided 
evidence for association of escitalopram plasma levels with an SNP in or near the CYP2C19 
gene and a metabolite (S-didesmethylcitalopram) level with SNPs near the CYP2D6 locus (Ji 
et al., 2014).  From a pharmacodynamics perspective a recent GWAS study using rare 
variants could demonstrate a genome-wide significant hit in the integrin α9 gene that 
replicated in one but not in the other replication control using GENDEP and STAR*D 
populations (Fabbri et al., 2017). In the 23andME cohort, another SNP in an intergenic region 
between the GPRIN3 and SNCA gene was demonstrated to be significantly associated with 
treatment response after bupropion treatment, however, no genome-wide association could be 
demonstrated for treatment resistant vs non-treatment resistant depression, citalopram or 
SSRIs (Li et al., 2016). Antidepressant response associated with the CTNNA3 gene without 
genome-wide significant individual SNP hits in a small Korean sample (Cocchi et al., 2016), 
while in another Korean sample SSRI administration associated with two polymorphisms in 
the intergenic region of the AUTS2 gene (Myung et al., 2015). Gupta et al. demonstrated 
associations with an indirect measure of citalopram/escitalopram efficacy, serotonin plasma 
concentrations, in TSPAN5 and ERICH3 gene polymorphisms in a small sample, in the only 
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functionally validated study, where altered TSPAN5 expression caused changes in 
serotonergic gene expression in cell lines (Gupta et al., 2016). The international SSRI 
Pharmacogenomics Consortium could identify an NRG1 polymorphism influencing SSRI 
response (Biernacka et al., 2015), which, however, remained non-significant after the 
necessary correction for multiple hypothesis testing. A small sample of Mexican Americans 
showed exome-wide association with remission after desipramine or fluoxetine treatment in a 
SNP harboring an epigenetic methylation site in the vicinity of TBX18, NT5E, and SNX14 
genes (Wong et al., 2014). A SNP near the NEDD4L gene was demonstrated to associate with 
antidepressant response using the STAR*D population, but in Caucasians results became 
unconvincing (Antypa et al., 2014). No SNP reached GWS in an investigation of sustained vs 
non-sustained response, but KEGG pathway long-term potentiation remained significant after 
correction (Hunter et al., 2013). Another study also failed to demonstrate significantly 
associating SNPs with SSRI or NRI treatment response (Tansey et al., 2012). Citalopram 
response or remission could similarly not associate with genome-wide significance, while 
below genome-wide significance threshold the most suggestive SNPs were in UBE3C, BMP7, 
RORA genes (Garriock et al., 2010). In the GENDEP project, outcome after nortriptyline and 
escitalopram treatment associated with SNPs in the uronyl 2-sulphotransferase gene and IL-
11, respectively (Uher et al., 2010). Genes CDH17, EPHB1, AK090788 and PDE10A were 
also suggested to be involved in response to antidepressants, but even selected multilocus 
analysis failed to demonstrate consistent results in the same study (Ising et al., 2009). And 
finally, the meta-analysis of the largest genetic databases on antidepressant response 
(STAR*D, GENDEP, MARS) could not provide results despite the larger sample sizes 
(Gendep Investigators. et al., 2013). 
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GWAS investigation of side effects also provided heterogeneous results. Citalopram-
induced side effects associated with two SNPs: one in the EMID2 gene with vision/hearing 
loss, the other in a region without genes with the overall side effect burden (Adkins et al., 
2012). SNPs in the MDGA2 gene showed relevance in SSRI or SNRI-induced sexual 
dysfunction in a small Japanese sample (Kurose et al., 2012), while bupropion-induced sexual 
dysfunction associated with SNPs in the SACM1L gene in the STAR*D population, however, 
with non-convincing significance (Clark et al., 2012). Antidepressant-emergent suicidal 
ideation showed the most significant association with an SNP in ANXA2 gene, which, 
however, could not reach genome-wide significance in a sample of 397 (Menke et al., 2012), 
while in the GENDEP project a SNP in GDA associated with suicidal ideation after 
medication with different antidepressants and two, one within KCNIP4 and one near ELP3 
associated after citalopram treatment (Perroud et al., 2012). Roles for polymorphisms of 
PAPLN and IL28RA genes were also raised in citalopram-induced suicidal ideation (Laje et 
al., 2009). Despite lack of reliable results genes and environmental effects which play a role 
in the pathogenesis of depression may play a role also in differences of response during 
treatment (Keers and Uher, 2012), and if the impact of such genetic variants in depression is a 
function of exposure to environmental influences then treatment may also be influenced by 
GxE interactions. 
 
5.4 GxE interactions in the pharmacotherapy of depression  
Previous studies have reported that environmental factors may predict response to 
antidepressant treatment (Keers and Uher, 2012). Earlier results from family studies suggested 
that there is a GxE interaction in response to antidepressants (Mandelli et al., 2009). However, 
except for a few positive results there is a remarkable lack of research concerning this topic. 
Depression developing following serious environmental stress events was reported to respond 
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better to psychotherapy or placebo, while depression developing rather independently of 
environmental triggers to antidepressants or electroconvulsive therapy, and better to TCAs 
than SSRIs (Andersen et al., 1990). Results of the GENDEP study have demonstrated that the 
effect of life events on antidepressant treatment efficacy varies by medication, with exposure 
to recent stressors predicting better escitalopram response, but no effect on nortriptyline 
response (Keers et al., 2010).  Furthermore, considering GxE effects, in 5HTTLPR SS carriers 
a worse response was detected to fluoxetine and escitalopram but only after stress exposure, 
and no such interaction effect was observable for nortriptyline (Keers et al., 2011; Mandelli et 
al., 2009). Altogether, while only a handful of genetic variants, mainly 5HTTLPR, BDNF, 
CRHR1, FKBP5 or NR3C1 have been implicated to influence response to antidepressant 
pharmacotherapy (Keers and Uher, 2012), and the effect of these variants could not be 
supported in metaanalyses or in the STAR*D study (Mandelli et al., 2009), the studies 
focusing on the pharmacogenetics of these polymorphism have not considered the effects of 
life events, stressors or environmental influences. Generally, besides 5HTTLPR, only in case 
of CHRH1 and FKBP5 have there been significant GxE interactions reported concerning 
efficacy of antidepressant treatment (Keers and Uher, 2012).  
 
5.5 Imaging genetics of antidepressant efficacy  
Considering the lack of significant genetic associations of antidepressant efficacy, and the 
above problems, instead of a direct application of genetics onto therapeutic response, the use 
of “surrogate markers”, at least, until the etiopathology of depression and causal carriers of 
antidepressant response are found, can be pursued. For the problem that we also lack 
biomarkers, imaging genetics can be a decent candidate. Imaging depression genetics can be 
defined as applying neuroimaging methods to explore intermediate phenotypes between 
genetic variations and disease through which we may be able to explore the connection 
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between genetic variants and depression at a neural level (Hariri and Weinberger, 2003). 
These intermediate phenotypes in depression are represented by functional and structural 
alterations in emotional processing-related brain regions including amygdala hyperreactivity, 
decreased functional connectivity between the amygdala and anterior cingulate cortex, and 
structural changes in the hippocampus and anterior cingulate cortex (Scharinger et al., 2011) 
Previous meta-analyses showed that antidepressant treatment tends to normalize altered 
activations in these regions (Delaveau et al., 2011; Fitzgerald, 2013).  
 
Two meta-analyses showed an association between 5HTTLPR and amygdala 
activation to negative emotional stimuli (Munafò et al., 2008; Murphy and Moya, 2011). 
Regarding antidepressant treatment, Ramasubbu and colleges have recently shown that brain 
activation changes to negative emotional faces after antidepressant therapy are related to 
5HTTLPR genotype (Ramasubbu et al., 2016). L-allele homozygotes showed decreased 
amygdala activation after one week and increased activation after eight weeks of citalopram 
therapy compared to baseline. In addition, quetiapine treatment led to decreased amygdala 
activation at week 1 and week 2 in S/L carriers. In a single-photon emission-computed 
tomography (SPECT) study, a positive relationship was observed that in individuals with L/L 
genotype between reduction of Hamilton Depression Rating Scale (HDRS)-17 score and 
serotonin transporter occupancy in the midbrain after 6 weeks of paroxetine treatment in 
depressed patients (Ruhe et al., 2009). Three studies investigating the effect of a single dose 
of citalopram and 5HTTLPR genotypes on brain activation and functional connectivity in 
healthy subjects reported that amygdala connectivity (Outhred et al., 2016) and activation 
(Outhred et al., 2014) during emotion processing correlated with the number of L alleles, 
while increased amygdala responsiveness to fearful faces was found in L/L carriers (Ma et al., 
2015). Besides the widely investigated 5HTTLPR, other polymorphisms including variants of 
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IL1B (Baune et al., 2010), NPY (Domschke et al., 2010b) and CNR1 (Domschke et al., 2008b) 
genes were also associated with remission and brain activation during face processing in 
depression.  In addition, studies aiming to explore genetic variants related anatomical changes 
to predict treatment response in depression reported that genetic polymorphisms including 
5HTTLPR (Tatham et al., 2017), BDNF (Tatham et al., 2017) and FKPB5 (Cardoner et al., 
2013; Zobel et al., 2010) may influence brain structures associated treatment outcome. 
 
Imaging genetics is a promising new method to explore the complex link between 
genes and clinical phenotypes such as depression or antidepressant efficacy. Findings showed 
that even with small sample sizes the impact of genetic polymorphisms on brain structure and 
function related to treatment response may be more significant than on treatment response 
itself (Lett et al., 2016). However, in spite of some consistent results concerning 5HTTLPR, it 
is hard to draw a conclusion. Multiple studies employed region of interest analysis instead of 
whole brain analysis. Moreover, every study used different designs and statistical analysis 
methods and thresholds. In order to make imaging genetics findings more comparable and to 
be able to draw clear conclusions from such studies more uniform study designs are required.  
 
5.6 Summary of the pharmacogenetics and pharmacogenomics of antidepressants  
The above results provide an overview about the problems in the pharmacogenetics and 
pharmacogenomics of antidepressants. There exist, maybe with the exception of ABCB1 
functional polymorphisms, no equivocal results about which polymorphisms in which genes 
influence response to antidepressants or their side effects.  
 
Among the pharmacokinetic genetic differences, polymorphisms within the ABCB1 
seem to consistently influence antidepressants that are transported by the protein. While CYP 
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enzyme-based metabolizer status shows a well-established connection with plasma levels of 
antidepressants, this does not manifest in a clear influence on side effects and, even less so, in 
therapeutic efficacy. Pharmacogenetic studies on pharmacodynamic markers are even less 
consistent. Most of the investigated genes belong to the serotonergic system, despite the fact 
that most current antidepressants may also have other mechanisms of action and that they may 
differ substantially from each other as demonstrated in e.g. expression studies (Petschner et 
al., 2016; Tamasi et al., 2014). Apart from serotonergic studies, however, BDNF and FKBP5 
seemed to be the most plausible candidates according to recent theories for depression 
pathophysiology, however, they also fail to replicate, which suggest that polymorphisms 
within these genes do not consistently contribute to antidepressant efficacy. The failure of 
candidate gene studies in the field fostered research on the genome-wide scale with GWASs, 
to find novel candidates in the background. But these studies remained indebted for providing 
targets that could be replicated in functional studies or that could be bound to the known 
pathophysiology of depression, except for citalopram and TSPAN5 and a demonstration of an 
association between CYP2D6 and CYP2C19 with plasma levels, a result already known from 
candidate gene studies.  
 
All these contradictory results possibly reflect that mechanisms of ADs remain still 
unclear and that we simply lack a unifying concept about how depression, its correlates and 
subtypes evolve and develop in an individual. The failure of novel drugs to exert effects on 
depression reflects exactly that. We can most probably develop novel therapeutics after we 
have solved at least most, if not all of the problems raised in the present review. That supports 
the notion that basic research in depression cannot be substituted by applied research and we 
cannot jump straight into therapeutic development without risking failures and huge costs.  
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6. A foreboding paradigm shift in the understanding of the etiopathogenetics of 
depression and approaching its treatment? 
As we have seen so far, the past several decades of research concerning depression, its 
etiopathogenetic background, as well as its treatment revealed more about what we don’t 
understand than about the complex architecture in the background of this highly prevalent and 
debilitating disorder and its therapy. By discovering how the majority of genes underpinning 
depression does not exert a main effect but may have a varying impact in interaction with 
different types, severity and timing of stressors we had to make yet another step towards 
conceptualizing depression as a stress-related disorder. It also appears that depression is a 
much more heterogeneous disorder than how we previously saw it simply based on the wide 
range of different symptomatic manifestations. The role that different types of previous stress 
plays in the manifestation of depression should probably be one of the possible bases for 
differentiating its main distinct subtypes, with the mediating role of different genetic and 
neurobiological pathways in more and less stress-related forms of depression. This may give 
rise to the need to develop a whole new conceptual framework, approach and reclassification 
of depressive disorders and its subtypes, building more on the differences of these subtypes 
rather than the similarities between them. 
 
Similarly, a paradigm shift seems necessary and even likely in the approach to, 
development of and also clinical study of new and already existing antidepressive 
medications. As genetics and environmental influences and neurochemical modulation appear 
to be different in more and less stress-related forms of depression, a better distinction between 
such depressive subtypes would be needed in clinical trials to avoid masking of the existing 
efficacy of antidepressants due to heterogeneous samples. Furthermore, stress end 
environmental influences in drug development and trials should be considered not only as 
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etiological factors, but through interacting with genes involved in treatment efficacy and side 
effects, the influence of such stressors should also be considered during antidepressant trials. 
Thus giving more emphasis to stress and gene x environment interactions both in the 
development and response to treatment in depression, we will likely have to reformulate how 
we think about the development and treatment of this illness.  
 
7. Concluding remarks  
From all the above study results and considerations regarding the genetic background of 
depression and antidepressant therapy four major conclusions could be drawn, which are 
relevant in two translational directions, namely new drug targets and personalized therapy 
(patient group identification for selection of specific treatments). 
 
First of all, when considering the major biological pathways of GWS genes implicated 
in depression or its pharmacotherapy (according to GeneCards), these, with a few exceptions, 
belong to neurogenesis, neuronal projection or synapse, cell contact (e.g., OLFM4, NEGR1, 
PCLO, DCC, PCDH9), Ca2+ channels (CACNA1E, CACNA2D1), DNA binding or 
transcription (TMEM161B-MEF2C, MEIS2-TMCO5A), meaning that their effects are 
probably several steps away from the development of the disorder, probably not specific for 
depression, and will be difficult to use as real drug targets. Lack of specificity in the 
therapeutic effect and possible serious side effects could thus be the most important factors. 
Surprises, however, are possible, such as in the case of kinase inhibitors in oncology, where 
actual side effects were not as strong as previously predicted, and thus, drug development 
became possible. Since polymorphism of the kinase regulator gene KSR2 has been identified 
as a GWS finding, certain kinase related developments could be possible. 
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Second, genes of target proteins of currently used antidepressants (e.g., those of the 
serotonin or noradrenaline transporter, or MAOA) do not show up in GWAS studies, thus, 
based on genomic studies no main effect of these proteins on depression could be expected. 
Rather, their effect could be therapeutic in stress-induced depression. Such clinical evidence 
is, however, lacking, suggesting that either genes emerging in GxE studies could be relevant 
targets in general and not only for reactive depression, or the negative bias and increased 
stress reaction in depression could, indeed, fade the border between endogenous and reactive 
depression when it comes to the question of effective antidepressant drug target proteins. 
Third, most candidate genes that came up and were proven in GxE interactions in depression 
(e.g., CRHR1, FKBP5, SLC6A4, SLC6A2, CNR1, GABRA6, IL1B, IL-6, FAAH, HTR1A) could 
be connected directly to the activity of the HPA-axis. Thus, these risk alleles and their 
combinations could help to identify groups with altered stress sensitivity and anxiety-related 
phenotypes. Furthermore, they may point to possible new drug targets. 
 
Finally, nuclear gene variations affecting mitochondrial functions can contribute to 
attenuated cognitive performance, and secondarily, to depression. It has been shown that if 
mitochondrial processes are affected, cognitive symptoms are more prominent in depression. 
These cognitive symptoms (e.g., rumination) in mood disorders remain often overlooked, 
despite the fact that they impose a serious burden on patients significantly compromising 
quality of life and impairing daily function in all domains. Risk polymorphisms may help to 
identify this subgroup of depression. Furthermore, they may point to possible new target 
proteins for antidepressant development in this specific group. Their effect is not dependent 
on stress exposure, therefore, patients with these risk alleles and altered mitochondrial 
functions are more frequently present among patients without any serious stress preceding the 
development of the disorder.  
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Figure 1. DSM-5 criteria for major depressive disorder (American Psychiatric Association., 
2013)  
 
Figure 2. Proposed mechanism for the development of depression (Bagdy et al., 2012) 
The figure depicts possible interrelations that may shape depression. Genes that may influence 
the disease directly (Gene set3) are rare and are usually involved in basic functions thus are 
unfeasible as therapeutic targets. Gene set 2 contains genes that contribute to personality 
traits, whose different combination in different individuals may results in the disease and can 
represent a subset of therapeutic targets in the future. The personality traits, temperaments and 
cognitive functions act together with environmental stress, for which individuals are 
sensitized through a different set of genes (Gene set1) in shaping depression. 
 
 
 
Figure 1. DSM-5 criteria for major depressive disorder (American Psychiatric Association., 
2013)  
A. Five (or more) of the following symptoms have been present during the same 2-
week period and represent a change from previous functioning; at least one of the 
symptoms is either (1) depressed mood or (2) loss of interest or pleasure. 
Note: Do not include symptoms that are clearly attributable to another medical condition. 
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1. Depressed mood most of the day, nearly every day, as indicated by either subjective 
report (e.g., feels sad, empty, hopeless) or observation made by others (e.g., appears 
tearful). (Note: In children and adolescents, can be irritable mood.) 
2. Markedly diminished interest or pleasure in all, or almost all, activities most of the 
day, nearly every day (as indicated by either subjective account or observation.) 
3. Significant weight loss when not dieting or weight gain (e.g., a change of more than 
5% of body weight in a month), or decrease or increase in appetite nearly every day. 
(Note: In children, consider failure to make expected weight gain.) 
4. Insomnia or hypersomnia nearly every day. 
5. Psychomotor agitation or retardation nearly every day (observable by others, not 
merely subjective feelings of restlessness or being slowed down). 
6. Fatigue or loss of energy nearly every day. 
7. Feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-reproach or guilt about being sick). 
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day 
(either by subjective account or as observed by others). 
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing 
suicide. 
 
B. The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning. 
C. The episode is not attributable to the physiological effects of a substance or to 
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another medical condition 
Note: Criteria A-C represent a major depressive episode. 
Note: Responses to a significant loss (e.g., bereavement, financial ruin, losses from a 
natural disaster, a serious medical illness or disability) may include the feelings of intense 
sadness, rumination about the loss, insomnia, poor appetite, and weight loss noted in 
Criterion A, which may resemble a depressive episode. Although such symptoms may be 
understandable or considered appropriate to the loss, the presence of a major depressive 
episode in addition to the normal response to a significant loss should also be carefully 
considered. This decision inevitably requires the exercise of clinical judgment based on the 
individual’s history and the cultural norms for the expression of distress in the contest of 
loss. 
D. The occurrence of the major depressive episode is not better explained by 
schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional 
disorder, or other specified and unspecified schizophrenia spectrum and other 
psychotic disorders. 
E. There has never been a manic episode or a hypomanic episode. 
Note: This exclusion does not apply if all of the manic-like or hypomanic-like episodes are 
substance induced or are attributable to the physiological effects of another medical 
condition. 
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Figure 2. Proposed mechanism for the development of depression (Bagdy et al., 2012) 
 
Gene sets include certain genes and Gene x Gene interactions 
The figure depicts possible interrelations that may shape depression. Genes that may influence 
the disease directly (Gene set3) are rare and are usually involved in basic functions thus are 
unfeasible as therapeutic targets. Gene set 2 contains genes that contribute to personality 
traits, whose different combination in different individuals may results in the disease and can 
represent a subset of therapeutic targets in the future. The personality traits, temperaments and 
cognitive functions act together with environmental stress, for which individuals are 
sensitized through a different set of genes (Gene set1) in shaping depression. 
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Table 1. Genome-wide significant findings for depression phenotypes in a main genetic effect 
model, since 2013  
Reference 
Discovery 
sample 
Findings in 
the 
discovery 
sample 
Replication sample 
Replicated 
findings 
Mbarek et al, 
2017 
(Mbarek et 
al., 2017) 
NESDA, 
NTR 
(European) 
PCLO - - 
Power et al, 
2017 (Power 
et al., 2017) 
9 studies of 
PGC 
(European) 
(including 
NESDA / 
NTR) 
intergenic 
rs7647854 
TwinGene   sy o aus  SHI -
  G  D  
Gen  D /DepGenes etworks
   niversity of  nster  
combined Danish sample; 
deCODE; Generation Scotland 
(all of these: European); 
CONVERGE (Chinese) 
nominal 
association 
of intergenic 
rs7647854 
Wray et al, 
2017  
PGC; 
deCODE; 
Generation 
Scotland; 
GERA; 
iPSYCH; 
44 
independent 
loci; the 
most 
remarkable 
genes, or 
- - 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
UK Biobank; 
23andMe (all 
of these: 
European) 
SNPs in 
genes: 
OLFM4; 
NEGR1; 
RBFOX1; 
LRFN5; 
CACNA1E; 
CACNA2D1
; DRD2; 
GRIK5; 
GRM5; 
PCLO 
Xiao et al, 
2017 (Xiao et 
al., 2017) 
23andMe; 
PGC; (both: 
European) 
CONVERG
E (Chinese) 
rs9540720 
in PCDH9 
independent 23andMe 
replication sample (European); 
a Chinese MDD sample 
nominal 
association 
of 
rs9540720 
in PCDH9 
Huo et al, 
2016 (Huo et 
al., 2016) 
PGC 
(European); 
CONVERG
E (Chinese) 
- - - 
Hyde et al, 
2016 (Hyde 
et al., 2016) 
23andMe; 
PGC (both: 
European) 
SNPs in 
OLFM4; 
TMEM161B
independent 23andMe 
replication sample (European) 
nominal 
associations: 
TMEM161B
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-MEF2C; 
MEIS2-
TMCO5A; 
NEGR1 
-MEF2C; 
NEGR1 
(Okbay et al., 
2016) PGC; UK 
Biobank; 
GERA (all of 
these: 
European) 
rs7973260 
in KSR2; 
rs62100776 
in DCC 
23andMe (European) 
nominal 
associations 
of 
rs7973260 
in KSR2 and 
rs62100776 
in DCC 
CONVERGE
, 2015 (Cai et 
al., 2015; 
Ware et al., 
2015) 
CONVERG
E (Chinese) 
rs12415800 
in SIRT1; 
rs35936514 
in LHPP 
independent Chinese MDD 
sample 
nominal 
associations 
of 
rs12415800 
in SIRT1 and 
rs35936514 
in LHPP 
Ware et al, 
2015 
MESA 
(European, 
African, 
Chinese and 
Hispanic 
Americans) 
rs1127233 
in MUC13 
in Hispanic 
Americans 
joint analyses with HRS in 
African and European 
Americans 
- 
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CACNA1E: calcium voltage-gated channel subunit alpha1 E; CACNA2D1: calcium voltage-
gated channel auxiliary subunit alpha2delta 1; CONVERGE: China Oxford and VCU 
Experimental Research on Genetic Epidemiology; DCC: DCC netrin 1 receptor; DRD2: 
dopamine receptor D2;  GenRED: Genetics of Recurrent Early-Onset Depression; GERA: 
Genetic Epidemiology Research on Adult Health and Aging; GRIK5: glutamate ionotropic 
receptor kainate type subunit 5; GRM5: glutamate metabotropic receptor 5; HRS: Health and 
Retirement Study; KSR2: kinase suppressor of ras 2; LHPP: phospholysine phosphohistidine 
inorganic pyrophosphate phosphatase; LRFN5: leucine rich repeat and fibronectin type III 
domain containing 5; MDD: major depressive disorder; MEF2C: myocyte enhancer factor 2C; 
MEIS2: meis homeobox 2; MESA: Multi-Ethnic Study of Atherosclerosis; MUC13: mucin 
13, cell surface associated; NEGR1: neuronal growth factor regulator 1; NESDA: the 
Netherlands Study of Depression and Anxiety; NTR: the Netherlands Twin Registry; OLFM4: 
olfactomedin 4; PCDH9: protocadherin 9; PCLO: presynaptic cytomatrix protein piccolo; 
PGC: Psychiatric Genomics Consortium; RBFOX1: RNA binding protein fox-1 homolog 1; 
SHIP-LEGEND: Study of Health in Pomerania–Life-Events and Gene-Environment 
Interaction in Depression; SIRT1: sirtuin 1; SNP: single nucleotide polymorphism; TMCO5A: 
transmembrane and coiled-coil domains 5A; TMEM161B: transmembrane protein 161B. 
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Table 2. Variants within genes or genes replicated in the different GWAS studies 
investigating depression after 2015 
Gene 
First study 
and sample 
Hit of the first 
study 
Second study and 
sample 
Hit of the second 
study 
PCLO 
Mbarek et al, 
2017 
(NESDA, 
NTR) 
rs2715157 + gene-
based test 
Wray et al, 2017 (PGC; 
deCODE; Generation 
Scotland; GERA; 
iPSYCH; UK Biobank; 
23andMe) 
gene-based test 
OLFM4 
Hyde et al, 
2016 
(23andMe; 
PGC) 
rs2806933; 
rs12552 
Wray et al, 2017 (PGC; 
deCODE; Generation 
Scotland; GERA; 
iPSYCH; UK Biobank; 
23andMe) 
rs12552 
NEGR1 
Hyde et al, 
2016 
(23andMe; 
PGC) 
rs11209948; 
rs2422321 not 
investigating 
rs1432639 
Wray et al, 2017 (PGC; 
deCODE; Generation 
Scotland; GERA; 
iPSYCH; UK Biobank; 
23andMe) 
rs1432639; 
rs12129573 
(statistically 
independent) 
PCLO: Piccolo Presynaptic Cytomatrix Protein; OLFM4: Olfactomedin 4; NEGR1: Neuronal 
Growth Regulator 1 
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Table 3. Environmental risk factors of depression 
Environmental risk factors 
Risk factor Articles 
Pre- or perinatal 
season of birth  (Uher, 2014) 
inadequate nutrition (Lopizzo et al., 2015; Uher, 2014)  
prenatal stress  (Schmitt et al., 2014; Uher, 2014)  
in utero exposure to 
infection 
(Lopizzo et al., 2015) 
preterm birth  (Schmitt et al., 2014; Uher, 2014),  
perinatal complications (Lopizzo et al., 2015) 
Childhood 
maltreatment, abuse  (Dunn et al., 2015; Juhasz et al., 2015; Lopizzo et al., 2015; 
Schmitt et al., 2014; Smoller, 2016; Uher, 2014)  
loss of a parent  (Lopizzo et al., 2015; Uher, 2014)  
parental divorce (Dunn et al., 2015; Smoller, 2016) 
negative family 
relationships 
(Dunn et al., 2015; Lopizzo et al., 2015; Mandelli and Serretti, 
2013; Smoller, 2016)  
social disadvantage, 
poverty 
(Dunn et al., 2015; Lopizzo et al., 2015; Smoller, 2016; Uher, 
2014)  
bullying  (Lopizzo et al., 2015; Uher, 2014)  
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urban upbringing (Lopizzo et al., 2015) 
Adolescence 
cannabis use (Lopizzo et al., 2015; Uher, 2014)  
Adulthood 
stressful life events  (Dunn et al., 2015; Lopizzo et al., 2015; Risch et al., 2009; 
Smoller, 2016; Uher, 2014)  
occupational stress, 
unemployment 
(Mandelli and Serretti, 2013) 
poor social 
contacts/support 
(Mandelli and Serretti, 2013) 
separation (Mandelli and Serretti, 2013) 
interpersonal problems (Mandelli and Serretti, 2013) 
ethnic minority status (Lopizzo et al., 2015) 
 
 
 
 
Table 4. Gene-environment interaction studies in depression 
GxE interactions 
Gene Environmental factor Articles Gene function 
5HTTLPR x stressful life events (Caspi et al., 2003) Repeat length 
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x childhood maltreatment polymorphism in the 
promoter region of 
serotonin transporter 
gene (SLC6A4) which 
encodes a protein 
involved in serotonin 
transportation. 
x financial difficulties (Gonda et al., 2016) 
Meta-
analyses  
- (Risch et al., 2009) 
- (Munafo et al., 2009) 
+ (only in Caucasians) (Karg et al., 2011) 
+ (Sharpley et al., 2014) 
- (Culverhouse et al., 
2018)  
+ (Bleys et al., 2018) 
BDNF 
Val66Met 
x childhood adversity 
x recent stressful events 
(Hosang et al., 2014; 
Lopizzo et al., 2015; 
Mandelli and Serretti, 
2013; Sharma et al., 
2016; Uher, 2014; 
Zhao et al., 2017) 
Encodes a nerve 
growth factor protein. 
BDNF is widely 
expressed in the 
central nervous 
system (including 
regions of mood 
regulation). Carrying 
Val66Met influences 
the activity of the 
coded protein. 
x childhood sexual abuse (Lopizzo et al., 2015; 
Mandelli and Serretti, 
2013) 
MAOA x childhood maltreatment 
x maternity difficulty 
(Mandelli and Serretti, 
2013; Naoi et al., 
Encodes monoamine 
oxidase A, which 
catabolizes 
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(postpartum depression) 
(but other four studies did not 
find interaction) 
2017; Uher, 2014) monoamines 
(serotonin, 
norepinephrine, 
dopamine). 
COMT x stress exposure  
x family stress (adolescent) 
x maternity stressors 
(postpartum depression) 
x early environmental risk (in 
men) 
(Mandelli and Serretti, 
2013) 
Involved in 
metabolism of 
noradrenalin and 
dopamine. 
FKBP5 x childhood trauma 
x stressful life events (1 out of 
2 studies) 
(Dunn et al., 2015; 
Lopizzo et al., 2015; 
Mandelli and Serretti, 
2013; Sharma et al., 
2016; Smoller, 2016) 
Regulation of stress-
response via HPA 
axis. 
x traumatic life events (Lopizzo et al., 2015) 
CRHR1 x childhood maltreatment 
(although mixed results – 
Mandelli et al, 2013) 
(Dunn et al., 2015; 
Smoller, 2016; Uher, 
2014) 
Regulation of stress-
response via HPA 
axis. 
SLC6A2 x severe stressful life events 
x women living in a rural area  
(2 studies) 
(Mandelli and Serretti, 
2013) 
Encodes 
noradrenaline 
transporter reuptaking 
neurotransmission of 
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noradrenalin and 
dopamine beta-
hydroxylase. 
CNR1 x stressful life events 
x physical abuse 
(2 studies) 
(Juhasz et al., 2009; 
Mandelli and Serretti, 
2013) 
Human Cannabinoid 
receptor 1 gene. 
GABRA6 x stressful life events (Gonda et al., 2017) Encodes Gamma-
aminobutyric acid 
receptor subunit 
alpha-6 protein. 
GAL, 
GALR1 
x stressful life events 
x childhood maltreatment 
(Juhasz et al., 2014) Galanin (a stress-
inducible 
neuropeptide) gene 
and its receptor. 
GALR2 x  stressful life events 
(not with childhood 
maltreatment) 
(Juhasz et al., 2014) Galanin receptor gene. 
GALR3 x childhood maltreatment 
(not with stressful life events) 
(Juhasz et al., 2014) Galanin receptor gene. 
IL1B x stressful life events 
x childhood maltreatment  
x chronic interpersonal stress 
(Kovacs et al., 2016a; 
Tartter et al., 2015) 
IL1b encodes 
interleukin-1β, a 
proinflammatory 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
cytokine.  
IL-6 x stressful life events 
x childhood maltreatment 
x chronic interpersonal stress 
(Baumeister et al., 
2016; Kovacs et al., 
2016b; Tartter et al., 
2015) 
 
IL-6 encodes 
interleukin-6, a 
modulator of pain 
processing. 
FAAH x childhood maltreatment (Lazary et al., 2016) Encodes fatty acid 
amide hydrolase 
enzyme which is 
responsible for 
anandamide 
degradation. 
HTR1A x stressful life events (but one 
negative finding) 
(Bukh et al., 2009; 
Mekli et al., 2011) 
Serotonin receptor 
gene 1A . 
HTR1B x stressful life events (Mekli et al., 2011) Serotonin receptor 
gene 1B. 
NOS1 x financial hardship (Sarginson et al., 
2014) 
Encodes neuronal 
nitric oxide synthase 1 
with multiple roles 
(for example synaptic 
signaling, regulation 
of serotonin pathway 
and HPA-axis). 
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BDNF Val66Met: Brain derived neurotrophic factor 66 valine-methionine polymorphism; 
MAOA: Monoamino-oxidase A; COMT: Cathecol-o-methyltransferase; FKBP5: FK506 
binding protein 5; CRHR1: Corticotropin releasing hormone receptor 1; SLC6A2 solute 
carrier family 6 member 2; CNR1: Cannabinoid receptor 1; GABRA6: Gamma-Aminobutyric 
Acid Type A Receptor Alpha6 Subunit; GAL: Galanin; GALR1: galanin receptor 1; GALR2: 
galanin receptor 2; GALR3: galanin receptor 3; IL1B: interleukin 1 beta; IL-6: interleukine 6; 
FAAH: Fatty acid amide hydrolase; HTR1A: serotonin transporter 1A receptor; HTR1B: 
Serotonin transporter 1B receptor; NOS1: Nitric oxide synthase 1 
+ indicates confirmatory while – indicates negative metaanalyses 
 
 
 
Table 5. Summary of genes implicated in depression: association with diagnosis, 
endophenotypes, symptoms cluster and biological involvement 
 
Depression 
diagnosis or 
sum of 
symptom 
scores 
Psychological 
endophenotypes 
Symptom 
clusters 
Biological involvement 
according to GeneCard’s 
summaries 
Gene G 
Gx
E 
Gx
G 
G 
Gx
E 
Gx
G 
G 
G
x
E 
G
x
G 
M
o
n
o-
a
Gl
u/ 
G
A
B
Neu
roge
nesi
s/ 
neu
Imm
une 
funct
ions 
Othe
r/ 
not-
know
n 
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m
in
es 
A ron
al 
proj
ecti
on/ 
syn
apse
/cell
-cell 
cont
act 
APOE + #         
    + 
(lipid 
meta
bolis
m) 
GNB3 + #      
(+) 
on 
cor
e, 
psy
chic 
anx
iety 
and 
  
    + (G-
protei
n 
coupl
ed 
signal
ing) 
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del
usio
n 
sym
pto
ms 
MTHFR + #  
+ 
by 
CO
MT  
(-) on 
rumi
natio
n 
     
    + 
(folat
e 
cycle
) 
SLC6A4 
(5-
HTTLP
R) 
+/- 
# 
+/- 
by 
stre
ssfu
l 
life 
eve
nts 
and 
by 
chil
dho
od 
malt
(+) 
by 
unk
no
wn 
gen
e 
on 
chr
om
oso
me 
4 
+/- 
on 
neur
oticis
m; 
- on 
harm 
avoid
ance; 
- on 
impu
lsivit
y; 
- on 
(+) 
on 
imp
ulsi
vity 
by 
chil
dho
od 
trau
ma; 
+ 
on 
rum
(+) 
on 
im
pul
siv
ity 
by 
M
AO
A; 
(+) 
on 
im
pul
(+) 
on 
som
atiz
atio
n; 
(+) 
on 
dys
pho
ria 
  
+ 
(5
H
T
) 
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reat
men
t; 
(+) 
by 
fina
ncia
l 
diffi
culti
es  
rumi
natio
n; 
(+/-) 
on 
eithe
r 
depre
ssive, 
hype
rthy
mic, 
irrita
ble 
or 
anxio
us 
temp
eram
ent; 
(+)/- 
on 
cyclo
thym
ic 
inat
ion 
by 
vari
ous 
typ
es 
of 
stre
ss 
siv
ity 
by 
HT
R2
A; 
(+) 
on 
im
pul
siv
ity 
by 
TP
H2
; 
(-) 
on 
im
pul
siv
ity 
by 
eit
her 
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temp
eram
ent 
HT
R1
A 
or 
HT
R1
B; 
(-) 
on 
ru
mi
nat
ion 
by 
BD
NF
; 
(-) 
on 
TE
M
PS
-A 
by 
DR
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D4 
SLC6A3 + #   
(+) 
on 
impu
lsivit
y 
     
+ 
(
D
A
) 
    
HTR1A - 
(+/-
) by 
stre
ssfu
l 
life 
eve
nts 
 
(-) on 
impu
lsivit
y 
(-) 
on 
imp
ulsi
vity 
by 
chil
dho
od 
trau
ma 
(-) 
on 
im
pul
siv
ity 
by 
eit
her 
TP
H2
, 5-
HT
TL
PR
, 
M
AO
A, 
(-) 
on 
suic
idal
ity 
in 
dep
ress
ion 
  
+ 
(5
H
T
) 
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HT
R1
B 
or 
HT
R2
A 
HTR1B -   
(+/-) 
on 
impu
lsivit
y 
(-) 
on 
imp
ulsi
vity 
by 
chil
dho
od 
trau
ma 
(+) 
on 
im
pul
siv
ity 
by 
HT
R2
A; 
(-) 
on 
im
pul
siv
ity 
by 
eit
   
+ 
(5
H
T
) 
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her 
TP
H2
, 5-
HT
TL
PR
, 
M
AO
A 
or 
HT
R1
A 
HTR2A -   
+/(-) 
on 
impu
lsivit
y 
(-) 
on 
imp
ulsi
vity 
by 
chil
dho
od 
trau
(+) 
on 
im
pul
siv
ity 
by 
5-
HT
TL
(+) 
on 
som
atiz
atio
n; (-
) on 
suic
idal
ity 
  
+ 
(5
H
T
) 
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ma PR
; 
(+) 
on 
im
pul
siv
ity 
by 
HT
R1
B; 
(-) 
on 
im
pul
siv
ity 
by 
eit
her 
TP
H2
, 
M
in 
dep
ress
ion 
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AO
A 
or 
HT
R1
A 
HTR2C -         
+ 
(5
H
T
) 
    
TPH1 -      
(+) 
on 
mid
dle 
inso
mni
a; 
(+) 
on 
som
atic 
anx
iety
; (-) 
  
+ 
(5
H
T
) 
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on 
MA
DR
S 
sym
pto
m 
clus
ters 
MAOA - 
+/- 
by 
chil
dho
od 
malt
reat
men
t; 
(+) 
by 
mat
erni
ty 
diffi
cult
  
(-) 
on 
imp
ulsi
vity 
by 
chil
dho
od 
trau
ma 
(+) 
on 
im
pul
siv
ity 
by 
5-
HT
TL
PR
; 
(-) 
on 
im
pul
(-) 
on 
MD
D 
sub
gro
ups 
  
+ 
(5
H
T, 
D
A
, 
N
A
) 
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y siv
ity 
by 
eit
her 
TP
H2
, 
HT
R1
A, 
HT
R1
B 
or 
HT
R2
A 
COMT - 
(+/-
) by 
stre
ssfu
l 
life 
eve
+ 
by 
MT
HF
R 
- on 
impu
lsivit
y; 
(+)/- 
on 
rumi
  
(+) 
on 
som
atiz
atio
n 
  
+ 
(
D
A
, 
A
, 
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nts; 
(+) 
by 
fam
ily 
stre
ss; 
(+) 
by 
mat
erni
ty 
stre
ss; 
(+) 
by 
earl
y 
envi
ron
men
tal 
risk 
natio
n 
N
A
) 
BDNF - 
+ by 
stre
(+) 
by 
+/- 
on 
(+) 
on 
(-) 
on 
   
  + 
(neu
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ssfu
l 
life 
eve
nts 
and 
by 
chil
dho
od 
malt
reat
men
t 
CR
HR
1 
rumi
natio
n; 
(-) on 
eithe
r 
depre
ssive, 
cyclo
thym
ic, 
hype
rthy
mic, 
irrita
ble 
or 
anxio
us 
temp
eram
ent 
rum
inat
ion 
by 
adv
erse 
eve
nts 
ru
mi
nat
ion 
by 
5-
HT
TL
PR 
rona
l 
surv
ival) 
SLC6A2 - 
(+) 
by 
stre
    
(+) 
on 
som
  
+ 
(
N
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ssfu
l 
life 
eve
nts; 
(+) 
by 
livi
ng 
in 
rura
l 
area
s 
atiz
atio
n 
A
) 
DRD3 -         
+ 
(
D
A
) 
    
GABRA
3 
-         
 + 
(G
A
B
A) 
   
ACE -             + 
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(RAS
) 
CLOCK -         
    + 
(circa
dian 
rhyth
m) 
DRD4 + #   
(-) on 
impu
lsivit
y; 
(+/-) 
on 
eithe
r 
cyclo
thym
ic or 
irrita
ble 
temp
eram
ent; 
(-) on 
eithe
 
(+) 
on 
im
pul
siv
ity 
by 
AN
KK
1; 
(-) 
on 
TE
M
PS
-A 
by 
5-
   
+ 
(
D
A
) 
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r 
depre
ssive, 
hype
rthy
mic 
or 
anxio
us 
temp
eram
ent 
HT
TL
PR 
SLC6A1
5 
**         
    + 
(neutr
al 
amin
o 
acid 
trans
port) 
PCLO **         
  + 
(syn
apti
c 
zone 
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cyto
matr
ix) 
OLFM4 **         
  + 
(cell 
adhe
sion
) 
  
NEGR1 **         
  + 
(axo
n 
gro
wth) 
  
PCDH9 **         
  + 
(cell 
adhe
sion 
in 
neur
al 
tissu
es) 
  
TMEM1
61B-
MEF2C 
**         
    + 
(DN
A 
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bindi
ng) 
KSR2 **         
    (+ 
kinas
e 
regul
ation) 
DCC **         
  + 
(axo
n 
guid
ance
) 
  
SIRT1 **         
    unkn
own 
LHPP **         
    + 
(phos
phata
se) 
RBFOX
1 
*   
* on 
extra
versi
on 
     
    + 
(alter
nativ
e 
splici
ng 
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regul
ation) 
LRFN5 *         
  + 
(neu
rite 
outg
rowt
h, 
cell 
adhe
sion
) 
  
CACNA
1E 
*   
** on 
neur
oticis
m 
     
    + 
(calci
um 
chann
el, 
skelet
al 
muscl
e 
contr
actio
n) 
CACNA *             + 
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2D1 (calci
um 
chann
el) 
DRD2 *   
(+/-) 
on 
rumi
natio
n 
     
+ 
(
D
A
) 
    
GRIK5 *         
 + 
(G
lu
) 
   
GRM5 *         
 + 
(G
lu
) 
   
MEIS2-
TMCO5
A 
*         
    + 
(MEI
S2 – 
transc
riptio
nal 
regul
ator; 
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TMC
O5A 
- 
unkn
own) 
MUC13 *         
    + 
(epith
elial 
muci
n) 
CNR1 (+) 
(+) 
by 
stre
ssfu
l 
life 
eve
nts; 
(+) 
by 
chil
dho
od 
malt
reat
       
    + 
(endo
canna
binoi
d) 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
men
t  
GABRA
6 
(-) 
+ by 
stre
ssfu
l 
life 
eve
nts 
       
 + 
(G
A
B
A) 
   
GAL (+) 
(+) 
by 
stre
ssfu
l 
life 
eve
nts 
and 
by 
chil
dho
od 
malt
reat
men
       
    + 
(gala
nin 
signal
ing) 
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t  
GALR1 (-) 
(+) 
by 
stre
ssfu
l 
life 
eve
nts 
and 
by 
chil
dho
od 
malt
reat
men
t  
       
    + 
(gala
nin 
signal
ing) 
GALR2 (-) 
(+) 
by 
stre
ssfu
l 
life 
eve
       
    + 
(gala
nin 
signal
ing) 
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nts; 
(-) 
by 
chil
dho
od 
malt
reat
men
t  
 
GALR3 (-) 
(-) 
by 
stre
ssfu
l 
life 
eve
nts 
(+) 
by 
chil
dho
od 
malt
       
    + 
(gala
nin 
signal
ing) 
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reat
men
t  
IL1B - 
(+) 
by 
stre
ssfu
l 
life 
eve
nts 
and 
by 
chil
dho
od 
malt
reat
men
t; 
(+) 
by 
chro
nic 
inte
       
   + 
(proi
nfla
mma
tory 
interl
eukin
) 
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rper
son
al 
stre
ss 
IL-6 - 
(+) 
by 
stre
ssfu
l 
life 
eve
nts 
+ 
chil
dho
od 
malt
reat
men
t; 
(+) 
by 
chro
nic 
       
   + 
(proi
nfla
mma
tory 
interl
eukin
) 
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inte
rper
son
al 
stre
ss 
FAAH (-) 
(+) 
by 
chil
dho
od 
malt
reat
men
t 
       
    + 
(endo
canna
binoi
d 
signal
ing) 
NOS1 (-) 
(+) 
by 
fina
ncia
l 
hard
ship 
       
    + 
(nitri
c 
oxide 
synth
ase) 
MMP-9 (+)  
(+) 
by 
M
      
    + 
(extra
cellul
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MP
-2; 
(+) 
by 
M
MP
-7; 
(+) 
by 
TI
MP
-2 
ar 
matri
x 
break
down
) 
TIMP-2 (+)  
(+) 
by 
M
MP
-2; 
(+) 
by 
M
MP
-7; 
(+) 
by 
M
      
    + 
(extra
cellul
ar 
matri
x 
break
down
) 
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MP
-9 
MMP-7 
(+) 
on 
mi
ddl
e-
ag
e 
de
pre
ssi
on 
 
(+) 
by 
M
MP
-2; 
(+) 
by 
M
MP
-9; 
(+) 
by 
TI
MP
-2 
      
    + 
(extra
cellul
ar 
matri
x 
break
down
) 
MMP-2 (-)  
(+) 
by 
M
MP
-7; 
(+) 
by 
M
      
    + 
(extra
cellul
ar 
matri
x 
break
down
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MP
-9; 
(+) 
by 
TI
MP
-2 
) 
BCL1 (-)  
(+) 
by 
CH
RN
A4 
      
    + 
(cell 
cycle 
regul
ation) 
CHRNA
4 
(-)  
(+) 
by 
BC
L1 
      
    + 
(choli
nergi
c 
neuro
trans
missi
on) 
HTR2B    
(+) 
on 
impu
lsivit
y 
     
+ 
(5
H
T
) 
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GRIA3       
(+) 
on 
guil
t (in 
fem
ale 
onl
y) 
  
 + 
(G
lu
) 
   
GRIK2       
(+) 
on 
som
atic 
anx
iety 
  
 + 
(G
lu
) 
   
5HT2A       
(+) 
on 
veg
etat
ive 
sym
pto
ms 
  
+ 
(5
H
T
) 
    
ZNF169 (-)  
(+/-
) by 
rs4
      
    + 
(unkn
own, 
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769
180 
proba
bly 
transc
riptio
n 
regul
ation) 
rs47691
80 
(-) 
 
(+/-
) by 
ZN
F16
9 
      
    + (no 
assoc
iated 
gene) 
PRSS12 
(-) 
 
+ 
by 
rs7
587
468 
      
  + 
(exc
itato
ry 
syna
pse 
prot
ease
) 
  
rs75874
68 
(-) 
 
+ 
by 
PR
SS1
      
    + (no 
assoc
iated 
gene) 
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2 
TMCC3 
(-) 
 
(+/-
) by 
rs9
940
287 
      
    + 
(unkn
own) 
rs99402
87 
(-) 
 
(+/-
) by 
TM
CC
3 
      
    + (no 
assoc
iated 
gene) 
KCNAB
1 
(-) 
 
+ 
by 
rs1
084
302
1 
      
    + 
(pota
ssium 
chann
el) 
rs10843
021 
(-) 
 
+ 
by 
KC
NA
B1 
      
    + (no 
assoc
iated 
gene) 
               
PHF21
B 
 
+ 
(in 
       
    + 
(unkn
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pop
ulati
ons 
exp
ose
d to 
stre
ss) 
own) 
CEP350  
* 
(stre
ss 
of 
the 
prev
ious 
one 
year
) 
       
    + 
(centr
osom
e and 
nucle
ar 
horm
one 
recep
tor  
regul
ation) 
RGS10  
* 
(stre
ss 
of 
the 
       
    + 
(regul
ator 
of G-
protei
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prev
ious 
one 
year
) 
n 
signal
ing) 
TAAR6   
(+) 
by 
HS
PA
1A 
      
    + 
(putat
ive 
trace 
amin
e 
recep
tor 
HSPA1
A 
  
(+) 
by 
TA
AR
6 
      
    + 
(stres
s 
prote
ction) 
               
XKR6    
** on 
neur
oticis
m 
     
    + 
(unkn
own) 
MSRA    
** on 
neur
     
    + 
(meth
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oticis
m 
ionin
e 
sulfo
xide 
reduc
tion, 
repair 
of 
oxidi
zed 
protei
ns) 
LINGO2    
** on 
neur
oticis
m 
     
    + 
(unkn
own, 
possi
bly 
invol
ved 
in 
negat
ive 
regul
ation 
of 
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axona
l 
regen
eratio
n) 
AGBL2    
** on 
neur
oticis
m 
     
    + 
(degl
uatm
ylatio
n) 
CELF4    
** on 
neur
oticis
m 
     
    + 
(mR
NA 
editin
g and 
transl
ation) 
ZC3H7
B 
   
** on 
neur
oticis
m 
     
    + 
(unkn
own) 
BAIAP2    
** on 
neur
oticis
m 
     
  + 
(neu
rite 
gro
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wth, 
adap
ter 
prot
ein) 
GNL3    
* on 
neur
oticis
m 
     
    + 
(stem 
cell 
regul
ation) 
FAM12
0AOS 
   
* on 
neur
oticis
m 
     
    + 
(unkn
own) 
ANKK1    
* on 
neur
oticis
m; 
+ on 
impu
lsivit
y 
(-) 
on 
imp
ulsi
vity 
by 
psy
cho
soci
al 
stre
(+) 
on 
im
pul
siv
ity 
by 
DR
D4 
   
    + 
(gene 
itself 
not 
know
n, but 
closel
y 
linke
d to 
DRD
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ss 2) 
RPS6KL
1 
   
* on 
neur
oticis
m 
     
    + 
(unkn
own)  
ZNF646    
* on 
neur
oticis
m 
     
    + 
(trans
cripti
on 
regul
ation) 
CRHR1 
+ 
/(-) 
+ / 
(-) 
by 
chil
dho
od 
malt
reat
men
t 
(+/-
) by 
AV
PR
1b; 
(+) 
by 
BD
NF 
* on 
neur
oticis
m 
     
   + 
(corti
cotro
pin 
relea
sing 
horm
one 
recep
tor) 
 
SPPL2C    
* on 
neur
oticis
m 
     
    + 
(sign
al 
pepti
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de 
cleavi
ng) 
MAPT    
* on 
neur
oticis
m 
     
  + 
(axo
n 
mai
nten
ance
) 
  
L3MBT
L2/CHA
DL 
   
** on 
neur
oticis
m 
     
    + 
(L3M
BTL2 
– 
transc
riptio
nal 
regul
ator; 
CHA
DL – 
chon
drocy
te 
differ
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PT
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entiat
ion) 
LINC00
461 
   
* on 
cons
cienti
ousn
ess 
     
    + 
(unkn
own) 
GBE1    
* on 
extra
versi
on 
     
    + 
(glyc
ogen 
solub
ility 
and 
accu
mulat
ion) 
MTMR9    
** on 
extra
versi
on 
     
    + 
(unkn
own) 
PCDH1
5 
   
** on 
extra
versi
on 
     
  + 
(cell
-cell 
adhe
sion
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) 
WSCD2    
** on 
extra
versi
on 
     
    + 
(unkn
own) 
GRIK3    
* on 
neur
oticis
m 
     
 + 
(G
lu
) 
   
ENAH/S
RP9 
   
* on 
neur
oticis
m 
     
  + 
(EN
AH 
-
axo
n 
guid
ance
) 
 + 
(SRP
9 – 
secret
ory 
protei
n 
guidi
ng) 
PVRL3    
* on 
neur
oticis
m 
     
  + 
(syn
apse 
mai
nten
ance
) 
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TMEM1
92/KLH
L2/MSM
O1 
   
* on 
neur
oticis
m 
     
   + 
(KL
HL2 
– 
antig
en 
proce
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) 
+ 
(unkn
own 
– 
TME
M192
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KLH
L2 – 
olygo
dendr
ocyte 
proje
ction 
devel
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O1 – 
chole
sterol 
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neur
oticis
m 
(neu
ron 
diffe
renti
atio
n) 
ELAVL2    
* on 
neur
oticis
m 
     
    + 
(neur
onal 
specif
ic 
RNA 
bindi
ng) 
MAGI1    
* on 
neur
oticis
m 
     
  + 
(cell
-cell 
junc
tion) 
  
KATNA
L2 
   
* on 
cons
cienti
ousn
ess 
     
  + 
(mic
rotu
bule 
reor
gani
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
zati
on) 
               
AVPR1b (-)  
(+/-
) by 
CR
HR
1 
      
    + 
(argin
ine 
vasop
ressin 
recep
tor) 
TPH2    
(-) on 
impu
lsivit
y 
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on 
imp
ulsi
vity 
by 
chil
dho
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on 
im
pul
siv
ity 
by 
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im
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on 
suic
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CREB1    
(+) 
on 
rumi
natio
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+ 
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(circa
dian 
rhyth
micit
y and 
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by 
KC
NJ
6 
transc
riptio
nal 
regul
ation)  
KCNJ6      
+ 
on 
ru
mi
nat
ion 
by 
CR
EB
1 
   
    + 
(pota
ssium 
chann
el) 
FKBP5 - 
+ by 
chil
dho
od 
trau
ma; 
(+/-
) by 
stre
ssfu
 
- on 
rumi
natio
n 
+ 
on 
rum
inat
ion 
by 
chil
dho
od 
eve
    
   + 
(gluc
ocort
icoid 
recep
tor 
regul
ation
, 
steroi
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l 
life 
eve
nts 
nts d 
horm
one 
recep
tor 
regul
ation
) 
MTHFD
1L 
   
+ on 
rumi
natio
n 
     
    + 
(tetra
hydro
folate 
synth
esis) 
NR3C2    
(+/-) 
on 
rumi
natio
n 
     
    + 
(mine
raloc
ortoc
oid 
recep
tor) 
OXTR    
(+) 
on 
depre
ssive 
     
    + 
(oxyt
ocin 
recep
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temp
eram
ent; 
(-) on 
eithe
r 
cyclo
thym
ic, 
hype
rthy
mic, 
irrita
ble 
and 
anxio
us 
temp
eram
ent 
tor) 
GSK3β    
(-) on 
eithe
r 
depre
ssive, 
     
  + 
(neu
rona
l 
pola
 + 
(glyc
ogen 
home
ostasi
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irrita
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or 
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and 
neur
ite 
outg
rowt
h) 
s) 
PPARD    
(-) on 
eithe
r 
depre
ssive, 
cyclo
thym
ic, 
hype
rthy
mic, 
     
    + 
(myel
inizat
on, 
transc
riptio
nal 
regul
ator) 
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irrita
ble 
or 
anxio
us 
temp
eram
ent 
ARNTL    
(+) 
on 
cyclo
thym
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temp
eram
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(-) on 
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irrita
     
    + 
(circa
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rhyth
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regul
ation) 
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anxio
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temp
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ent 
hTIM    
(+) 
on 
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mic 
temp
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(-) on 
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irrita
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(circa
dian 
rhyth
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regul
ation) 
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or 
anxio
us 
temp
eram
ent 
PER3    
(-) on 
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depre
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thym
ic, 
hype
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irrita
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or 
anxio
us 
temp
eram
ent 
     
    + 
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rhyth
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regul
ation) 
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The table summarizes the results of genetic studies mentioned and referenced in the main text 
to provide an overview about the ethiopathological genetic variants in depression. Please, note 
that empty cells mean that the effect was not discussed in the present review. Gene functions 
were manually searched in GeneCards (retrieved on 23th of March, 2018). 
(+): evidence of association in a single study, without replication 
(-): investigated with a negative association result in a single study, without replication 
+: evidence of association in meta-analysis / meta-analyses or otherwise replicated studies 
-: investigated with a negative association result in meta-analysis / meta-analyses or other 
replication studies 
*: significant at a genome-wide level 
#: insignificant at a genome-wide level 
**: significant at a genome-wide level, and replicated either in a replication sample within the 
same study, or in another GWAS with also a genome-wide significance 
5HT: serotonin; NA: noradrenaline; DA: dopamine; A: adrenaline; Glu: glutamate 
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